Статті в журналах з теми "351.569 2"
Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: 351.569 2.
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "351.569 2".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
1
Montgomery, Robert R., Pamela A. Christopherson, Sandra L. Haberichter, Veronica H. Flood, and Joan Cox Gill. "Diagnostic Fidelity of Historically Diagnosed Patients with VWD Enrolled from 27 Centers in the ZPMCB-VWD." Blood 118, no. 21 (November 18, 2011): 381. http://dx.doi.org/10.1182/blood.v118.21.381.381.
Анотація:
Abstract Abstract 381FN2 The TS Zimmerman Program for the Molecular and Clinical Biology of von Willebrand Disease (ZPMCB-VWD) is a large NIH PPG to study existing subjects with von Willebrand Disease in the United States and to contrast these with prior and ongoing studies in Canada and the UK. 569 index cases (ICs) and 1732 family members were recruited from 8 Primary Clinical Centers and 19 Secondary Clinical Center. The inclusion criteria were that the subjects had a historical diagnosis of VWD and were registered as ongoing patients in the local HTC. 247 normal controls (NCs) were studied for comparison. Data included pre-existing diagnosis, historical diagnostic VWD testing, detailed bleeding history using a modified MCMDM-1VWD QBS, and subjects had plasma and DNA drawn for studies at a central laboratory for VWD, VWF phenotyping, and full length VWF exon sequencing. ICs included 391 type 1, 105 type 2, 43 type 3, and 30 unclassified. The recent HLBI Guidelines suggested that the diagnosis of VWD be based on a VWF level of <30 IU/dL (either VWF:Ag or VWF:RCo). Using the historical data, only 39.4% of ICs had either VWF:Ag or VWF:RCo of <30. Since historic data were studied using various lower limits of normal, we found 80% of subjects had either an Ag or RCO of <60. Central Laboratory testing of NCs and ICs was performed. While 7 of 247 NCs had reduced VWF:Ag or VWF:RCo, none of the NCs had <30 by either assay. Of the NCs with low VWF, 6 of 7 were blood type O and none had an abnormal bleeding score. While 372 of 569 ICs (65.4%) had reduced VWF assays by either method, only 201 (35.3%) had VWF assays that were below the NHLBI Guidelines of <30. Among ICs the correlation between current and historic VWF levels was an r2=0.199 for VWF:RCo and r2=0.268 for VWF:Ag. The current VWF:RCo correlated with the current VWF:Ag with an r2=0.827. The VWF:Ag and VWF:RCo were also restudied in a second laboratory with an r2=0.849 for VWF:Ag and r2=0.854 for VWF:RCo. The MCMDM-1VWD QBS was normal in all normal controls. In contrast, 350 of the ICs born prior to 1996, 247 (70.5%) had an abnormal QBS. Evaluated by pre-existing diagnosis, 65% of type 1 VWD, 78.6% of type 2 VWD and 100% of type 3 VWD had abnormal QBS. Interestingly, of the 351 VWD subjects born before 1996, the QBS was abnormal in 83.5% of males and 67.7% of females. In this age group, there were 248 females and 103 males followed with the diagnosis of VWD. VWF sequencing was carried out on all ICs and compared to the VWF Database maintained at the University of Sheffield. Sequence variations were present in 100% of the 391 type 1 VWD subjects with VWF levels of <10, 96% with VWF 11–20, 77% with VWF 21–30, 70% with VWF 31–40, 39% with VWF 41–50, and 42% of those with VWF 51–60. The decrease in VWF sequence variation between those <40 and those >40 seemed to be striking. The mean VWF:Ag levels of type 1 ICs with a VWF sequence variation was significantly lower (p<0.0001) than those with normal VWF sequence. More than 20 years ago, we demonstrated that besides blood type, age had the most significant effect on level of VWF in normal blood donors. We evaluated the VWF:Ag levels in our 247 NCs and VWF:Ag levels rose about 5% for each 10 years of age from age 20 to 60. In VWD it is not known if a similar process results in reduced bleeding symptoms with age or if this increase is related to the aging process or progressive vascular pathology. Stress is a significant confounding variable in the hemostatic evaluation of children – particularly for the diagnosis of VWD, but the effect of aging has not been defined. We therefore have demonstrated that the diagnosis of VWD was not consistently substantiated in a large group of patients diagnosed with VWD – particularly if using the VWF levels recommended by the NHLBI Guidelines. Historic VWF levels do not correlate with current levels of VWF. Moreover, 35% of these VWD subjects do not have evidence even of reduced VWF levels upon retesting. A number of questions remain. Are the NHLBI recommendations too strict? Is there an effect of aging on the normal level of VWF that affects the correct diagnosis of VWD? Will more rigid initial diagnostic testing improve the fidelity of the diagnosis of VWD? Is the diagnosis of VWD applied to a group of individuals with clinical bleeding with only some of these being associated with low VWF? Further longitudinal study of these VWD subjects is important. In those with significant clinical bleeding, other hemostatic abnormalities must be sought. The fidelity of the diagnosis of VWD needs improvement. Disclosures: Montgomery: GTI Diagnostics: Consultancy; CSL Behring: Consultancy; Biogen IDEC: Honoraria; Bayer: Consultancy; Baxter: Consultancy.
2
Stal, Julia, Kimberly A. Miller, Joel E. Milam, Molly Quinn, Sue E. Kim, Rachel C. Ceasar, and David R. Freyer. "Abstract 2253: Cancer-related follow-up health care utilization and fertility discussion, preservation, and reproductive concerns among diverse adolescent and young adult cancer survivors: A population-based study." Cancer Research 84, no. 6_Supplement (March 22, 2024): 2253. http://dx.doi.org/10.1158/1538-7445.am2024-2253.
Анотація:
Abstract Purpose: To examine cancer-related follow-up (CRFU) health care utilization associated with fertility experiences among diverse adolescent and young adult (AYA) cancer survivors. Methods: Project Milestones is an ongoing survey study evaluating life outcomes among AYAs diagnosed with cancer at age 21-39 in Los Angeles (LA) County. AYAs had an initial 5-year survival probability of ≥50% and are currently 3-10 years post-diagnosis. A registry-based recruitment strategy through the SEER-affiliated LA Cancer Surveillance Program was used. Results: Overall, 1442 AYAs responded (Table 1). Compared to AYAs who did not, AYAs who saw: (1) their treating provider for CRFU were more likely to report a fertility discussion (56.0% vs. 41.2%, p<.01); (2) another provider for CRFU were less likely to report a fertility discussion (38.1% vs. 52.0%, p<.01); (3) their treating provider for CRFU were more likely to report preserving fertility (14.7% vs. 8.4%, p<.01); (4) a primary care provider for CRFU were less likely to report preserving fertility (10.1% vs. 13.6% p<.05). Compared with AYAs who reported a CRFU visit 1+ years ago or never, AYAs with a visit <1 year ago: (1) had on average greater reproductive concerns (range 5-25, higher scores reflect greater concern, 13.8 vs. 13.4, p<.05); and were more likely to report (2) worry passing on a genetic risk for cancer to their child (55.6% vs. 47.8%, p<.01); and (3) caution about having children because they may not be around to raise them (23.6% vs. 16.6%, p<.01). Discussion: Iatrogenic infertility concerns persistent into survivorship, yielding a need to optimize oncofertility care throughout the reproductive lifespan. Receiving CRFU care from the treating provider is related to better outcomes, and higher reproductive concerns among AYAs with a recent visit may reflect greater awareness of risk due to more points of contact with a provider. Table 1: Sample characteristics - N (%) or M (SD) Total Hispanic Non-Hispanic 1442 622 (43.1) 820 (56.9) Age at survey 39.5 (5.8) 39.3 (5.8) 39.6 (5.7) Female 1007 (69.8) 429 (69.0) 578 (70.5) White 850 (62.4) 301 (55.0) 549 (67.3) Had employee-sponsored insurance 909 (63.0) 347 (55.8) 562 (68.5) Age at diagnosis 31.0 (5.2) 30.8 (5.2) 31.2 (5.1) Cancer type Leukemia/Lymphoma 396 (27.5) 173 (27.8) 223 (27.2) Reproductive 382 (26.5) 208 (33.4) 174 (21.2) Thyroid 184 (12.8) 86 (13.8) 98 (12.0) Breast 179 (12.4) 61 (9.8) 118 (14.4) Skin 130 (9.0) 21 (3.4) 109 (13.3) Colorectal 86 (6.0) 35 (5.6) 51 (6.2) Other 85 (5.9) 38 (6.1) 47 (5.7) Discussed fertility 717 (50.3) 327 (53.4) 390 (48.0) Preserved fertility 176 (12.3) 48 (7.8) 128 (15.7) Reproductive Concerns After Cancer (RCAC) score 14.1 (3.9) 14.3 (4.2) 14.0 (3.8) Last visit with a health care provider for cancer related follow-up care Within the past year 862 (60.3) 343 (56.2) 519 (63.4) 1-2 years ago 218 (15.3) 90 (14.8) 128 (15.6) More than 2 years ago 303 (21.2) 152 (24.9) 151 (18.4) Never 46 (3.2) 25 (4.1) 21 (2.6) Provider seen for cancer related follow-up care Same doctor who treated me 885 (61.4) 369 (59.3) 516 (62.9) Primary care provider 539 (37.4) 224 (36.0) 315 (38.4) Another type of provider 179 (12.4) 65 (10.5) 114 (13.9) Cancer survivorship clinic 88 (6.1) 46 (7.4) 42 (5.1) Citation Format: Julia Stal, Kimberly A. Miller, Joel E. Milam, Molly Quinn, Sue E. Kim, Rachel C. Ceasar, David R. Freyer. Cancer-related follow-up health care utilization and fertility discussion, preservation, and reproductive concerns among diverse adolescent and young adult cancer survivors: A population-based study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2253.
3
Storandt, Michael H., Urshila Durani, Daniela Stan, Nicole Larson, Charles Loprinzi, Fergus Couch, Janet E. Olson, Nandita Khera, and Kathryn J. Ruddy. "Abstract 1012: Financial hardship in breast cancer survivors." Cancer Research 82, no. 12_Supplement (June 15, 2022): 1012. http://dx.doi.org/10.1158/1538-7445.am2022-1012.
Анотація:
Abstract Background: Medical financial hardship, encompassing material, behavioral, and psychologic domains, is becoming an increasingly common consequence of illness in cancer patients. Identifying at-risk patients is the first step to develop proactive approaches to mitigate this problem. To try and address this need, Mayo Clinic Breast Disease Registry (MCBDR) is prospectively collecting data about financial concerns in addition to the usual sociodemographic and clinical information. Methods: We used data from Mayo Clinic Breast Disease Registry, a prospective cohort of consenting patients seen at Mayo Clinic Rochester within one year of initial breast cancer diagnosis. Participants completed baseline and annual follow-up surveys rating their financial concerns on a linear analogue scale from 0 (“none”) to 10 (“constant concerns”). We compared patient-reported financial concern at baseline to that on each patient’s most recent survey, with worsening concerns defined as a 1+-point increase. Logistic regression evaluated for predictors of worsening financial concerns. Results: 1,957 participants responded to financial concern questions on a baseline and at least one follow-up survey between 2015 and 2020. Mean age was 58.5 years (SD 12.5), and mean time between diagnosis and the most recent follow-up was 25.6 months (SD 16.2). 357 (18.2%) reported worsening financial concerns. Only lower baseline financial status was associated with a greater likelihood of worsening financial concerns (see Table). Conclusions: More than one in seven breast cancer survivors develop worsening financial concerns within 5-years of diagnosis, and those with less financial security at baseline appear to be most vulnerable. Funding: Breast Cancer Research Foundation (CLL) and NR015259 (KJR). Patient and tumor characteristics, compared by whether financial status worsened over time Full Cohort (n=1957) Worsening, ≥ 1-point change (n=357) Stable/Improved (n=1600) p value Full Cohort (n=1957) Worsening, ≥ 1-point change (n=357) Stable/Improved (n=1600) p value Age at diagnosis II or III 502 (25.7%) 98 (27.5%) 404 (25.3%) 0.239 ≤ 50 546 (27.9%) 105 (29.4%) 441 (27.6%) IV 67 (3.4%) 17 (4.8%) 50 (3.1%) 0.086 51-64 757 (38.7%) 136 (38.1%) 621 (38.8%) 0.562 Unknown 351 (17.9%) 65 (18.2%) 286 (17.9%) 0.536 ≥65 654 (33.4%) 116 (32.5%) 538 (33.6%) 0.506 ER and/or PR positive Race No/Unknown 482 (24.6%) 92 (25.8%) 390 (24.4%) White 1863 (95.2%) 337 (94.4%) 1526 (95.4%) Yes 1475 (75.4%) 265 (74.2%) 1210 (75.6%) 0.580 Non-white 24 (1.2%) 5 (1.4%) 19 (1.2%) 0.729 Her2 positive Other/Unknown/Choose not to respond 70 (3.6%) 15 (4.2%) 55 (3.4%) 0.478 No/Unknown 1746 (89.2%) 314 (88.0%) 1432 (89.5%) Educational status Yes 176 (9.0%) 37 (10.4%) 139 (8.7%) 0.321 Less than bachelor’s degree 880 (45.0%) 168 (47.1%) 712 (44.5%) Borderline 35 (1.8%) 6 (1.7%) 29 (1.8%) 0.898 Bachelor's degree or higher 1065 (54.4%) 187 (52.4%) 878 (54.9%) 0.384 Radiation Unknown 12 (0.6%) 2 (0.6%) 10 (0.6%) 0.832 No/Unknown 781 (39.9%) 140 (39.2%) 641 (40.1%) Financial status near time of diagnosis Yes 1176 (60.1%) 217 (60.8%) 959 (59.9%) 0.768 Pay bills, money for special things 1412 (72.2%) 244 (68.3%) 1168 (73.0%) Chemotherapy/targeted therapy Pay bills, no money for special things 367 (18.8%) 80 (22.4%) 287 (17.9%) 0.046 No/Unknown 1264 (64.6%) 221 (61.9%) 1043 (65.2%) Pay bills by making cuts 102 (5.2%) 19 (5.3%) 83 (5.2%) 0.729 Yes 693 (35.4%) 136 (38.1%) 557 (34.8%) 0.241 Unable to pay bills 56 (2.9%) 10 (2.8%) 46 (2.9%) 0.911 Hormone/endocrine therapy Unknown 20 (1.0%) 4 (1.1%) 16 (1.0%) 0.750 No/Unknown 710 (36.3%) 141 (39.5%) 569 (35.6%) Employment status at time of diagnosis Yes 1247 (63.7%) 216 (60.5%) 1031 (64.4%) 0.163 Employed full-time 462 (23.6%) 83 (23.2%) 379 (23.7%) Surgery type Employed part-time/unemployed/retired 525 (26.8%) 92 (25.8%) 433 (27.1%) 0.856 Lumpectomy 846 (43.2%) 145 (40.6%) 701 (43.8%) Not available 970 (49.6%) 182 (51.0%) 788 (49.3%) 0.716 Mastectomy 903 (46.1%) 165 (46.2%) 738 (46.1%) 0.535 Stage at time of diagnosis None/Unknown 208 (10.6%) 47 (13.2%) 161 (10.1%) 0.069 0 or I 1037 (53.0%) 177 (49.6%) 860 (53.8%) Citation Format: Michael H. Storandt, Urshila Durani, Daniela Stan, Nicole Larson, Charles Loprinzi, Fergus Couch, Janet E. Olson, Nandita Khera, Kathryn J. Ruddy. Financial hardship in breast cancer survivors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1012.
4
Bump Vena, Natalie, Paige Dawson, Thomas De Pree, Sarah Hitchner, George Holmes, Sudarshan R. Kottai, Daniel J. Murphy, Susan Paulson, Victoria C. Ramenzoni, and Kathleen Smythe. "Book Reviews." Environment and Society 12, no. 1 (September 1, 2021): 246–63. http://dx.doi.org/10.3167/ares.2021.120114.
Анотація:
Langston, Nancy. 2017. Sustaining Lake Superior: An Extraordinary Lake in a Changing World. New Haven, CT: Yale University Press. 292 pp. ISBN 978-0-300-21298-3.Moore, Margaret. 2019. Who Should Own Natural Resources? Cambridge, MA: Polity Press. 140 pp. ISBN 978-1-509-52916-2.Middleton Manning, Beth Rose. 2018. Upstream: Trust Lands and Power on the Feather River. Tucson: University of Arizona Press. 244 pp. ISBN 978-0-8165-3514-9.Van de Graaf, Thijs, and Benjamin K. Sovacool. 2020. Global Energy Politics. Cambridge: Polity Press. ISBN 978-1-5095-3048-9.Wapner, Paul. 2020. Is Wildness Over? Cambridge, MA: Polity Press. ISBN 978-1-5095-3212-4.DeSombre, Elizabeth R. 2020. What Is Environmental Politics? Cambridge: Polity Press. 202 pp. ISBN 978-1-5095-3413-5.Ptáčková, Jarmila. 2020. Exile from Grasslands: Tibetan Herders and Chinese Development Projects. Seattle: University of Washington Press. ISBN: 9 78-0-295-74819-1.Liegey, Vincent, and Anitra Nelson. 2020. Exploring Degrowth: A Critical Guide. London: Pluto Press. 224 pp. ISBN 978-0-7453-4201-6.Behringer, Wolfgang. 2019. Tambora and the Year without a Summer: How a Volcano Plunged the World into Crisis. Medford, MA: Polity Press. 334 pp. ISBN 978-1-509-52549-2.Duvall, Chris S. 2019. The African Roots of Marijuana. Durham, NC: Duke University Press. 351 pp. ISBN 978-1-4780-0394-6.
5
Vassiliades, Thomas A., James L. Nielsen, and James L. Lonquist. "Effects of Obesity on Outcomes in Endoscopically Assisted Coronary Artery Bypass Operations." Heart Surgery Forum 6, no. 2 (February 2, 2005): 99. http://dx.doi.org/10.1532/hsf.569.
Анотація:
<P>Background: Obesity has been shown to be an independent risk factor for adverse outcomes and prolonged hospitalization following conventional coronary artery bypass (CAB). For this reason and because of increased technical challenges, obesity has been considered a relative contraindication for minimally invasive bypass. The purpose of this study was to determine if in fact severe or morbid obesity is an independent risk factor for patients undergoing minimally invasive CAB. </P><P>Methods: Outcome data of 350 consecutive endoscopic, atraumatic CAB procedures performed at our institution over a 4-year period were reviewed with respect to patient body mass index (BMI). All operations consisted of thoracoscopic left or right internal mammary artery (IMA) harvesting followed by off-pump grafting of the left anterior descending (with/without diagonal coronary artery) or right coronary artery via a 4-cm thoracotomy. Patients were divided into 4 groups: small (BMI � 24 kg/m<SUP>2</SUP>), normal to mild obesity (24 kg/m<SUP>2</SUP> < BMI 34 kg/m<SUP>2</SUP>), severe obesity (34 kg/m<SUP>2</SUP> < BMI � 40 kg/m<SUP>2</SUP>), and morbid obesity (BMI >40 kg/m<SUP>2</SUP>). Results: Although the BMI >34 kg/m<SUP>2</SUP> groups had a higher incidence of hypertension, diabetes, and hypercholesterolemia, there was no statistical difference in operative risk between groups. Thirty-day mortality, conversion to sternotomy, transfusion rate, and wound, pulmonary, neurological, and myocardial complications were not significantly different between groups. The BMI >34 kg/m<SUP>2</SUP> patients required longer IMA harvest times and total operating times, but the intensive care unit length of stay was not significantly different between groups. Hospital length of stay was longer for the BMI � 24 kg/m<SUP>2</SUP> group than for the BMI 18 to 34 kg/m<SUP>2</SUP> group (P = .025). Conclusion: Despite increased technical difficulty caused by obesity, it is not an independent risk factor for patients undergoing minimally invasive CAB.</P>
6
Villaseñor-Perea, Carlos A., Araceli Ramírez-Jaspeado, Arturo Mancera-Rico, and Ma del Rosario Venegas- Ordoñez. "RESISTENCIA DE SEMILLAS DEL HÍBRIDO DE MAÍZ HS-2 A COMPRESIÓN AXIAL." Revista Fitotecnia Mexicana 40, no. 1 (March 22, 2017): 27–33. http://dx.doi.org/10.35196/rfm.2017.1.27-33.
Анотація:
La resistencia a compresión axial influye en distintas etapas del proceso de producción de semillas, lo que incluye la selección de progenitores, acondicionamiento y almacenaje, además del diseño de maquinaria y de las operaciones. En este estudio, realizado en 2013 en el laboratorio de materiales de la Universidad Autónoma Chapingo, Estado de México, se determinó la fuerza y deformación en los puntos de límite proporcional (LL), biocedencia (Y) y ruptura (R) de la semilla del híbrido de maíz (Zea mays L.) HS-2 de los estratos apical, medio y basal de la mazorca con humedades de 10 y 23 % sometidas a compresión axial. Para ello, las semillas se comprimieron en una máquina universal de ensaye entre superficies planas y pulidas. Las semillas del estrato medio estudiadas a 10 % de humedad, fueron más resistentes a la carga axial (LL = 301 N, Y = 434 N y R = 344 N) que las correspondientes a los estratos apical y basal (LL = 258 y 238 N, Y = 345 y 341 N, y R = 248 y 246 N, respectivamente). Semillas con 23 % de humedad presentaron mayor resistencia a la compresión que semillas con humedad de 10 % (LL = 429 vs. 301 N, Y = 598 vs. 434 N, y R = 568 vs. 344 N, respectivamente), además de una mayor elasticidad (LL = 0.827 vs. 0.215 mm) y desplazamiento en general (Y = 1.165 vs. 0.303 mm, y R = 1.215 vs. 0.341 mm, respectivamente).
7
Mastrianni, David, Richard Falivena, Timothy Brooks, Brian McDermott, Josenia Tan, Richard Vandell, and Michael Holland. "Pooled Testing for SARS-CoV-2 in Hospitalized Patients." Journal of Hospital Medicine 15, no. 9 (July 20, 2020): 538–39. http://dx.doi.org/10.12788/jhm.3501.
Анотація:
Viral testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly early in the COVID-19 pandemic, was limited by supply of reagents. We pooled nasopharyngeal samples from patients at low risk of SARS-CoV-2 infection in groups of 3 for testing. Three weeks of testing using this strategy resulted in 530 patient tests in 179 cartridges; 4 positive test groups required the use of 11 additional cartridges with an overall positive rate of 0.8% in a low-risk population. This strategy resulted in the use of 340 fewer cartridges than if each test were performed on one patient sample. Pooled testing of lowrisk populations allows for continued testing even when supplies are relatively scarce. Journal of Hospital Medicine 2020;15:538-539. © Society of Hospital Medicine
8
Ganesh, Prakash, Rachel Mernoff, Renske Dikkers, William Nundwe, and Rachel Pope. "A Comparison of Postoperative Surgical Outcomes among Women Undergoing Obstetric Fistula Repair with and without HIV." International Journal of Maternal and Child Health and AIDS (IJMA) 10, no. 2 (October 30, 2021): 191–97. http://dx.doi.org/10.21106/ijma.509.
Анотація:
Background and Objective: Obstetric fistula affects approximately 2 million women worldwide, predominantly in places with a high Human Immunodeficiency Virus (HIV) burden. In Malawi, where thousands of women live with fistulas, HIV prevalence is 11-13%. Although repair is usually successful, surgical outcomes among immunocompromised women are poorly understood. Inconsistent guidelines regarding the Cluster of Differentiation 4 (CD4) threshold necessary for repair make it difficult for surgeons to make informed decisions. This study compares the postoperative outcomes of women undergoing obstetric fistula repair with and without HIV, stratified by CD4 count. Methods: This is a retrospective case-control study using a database of women who underwent vesicovaginal fistula repair at the Fistula Care Center from 2010-2018. HIV-positive participants, stratified by CD4<350 and CD4>350, were matched to HIV-negative controls by age within 5 years and Goh classification. Controls were matched to cases in a 3:1 ratio. Bivariate analysis and logistic regression were conducted on indicators based on HIV status and CD4 count stratification. Outcomes included dye test results, pad weights, and continence status at 2 weeks post-repair. Results: 54 seropositive women were matched to 135 seronegative women. Of the 54 HIV positive women, 22.2% (n=12) had a CD4 count < 350. We found no statistically significant difference in surgical outcomes between HIV-positive and negative patients. 93.5% of HIV positive and 90% of HIV negative women healed completely. In our sub-analysis of 12 seropositive women with CD4<350, we found a statically significant difference in successful closure, with 25% of women with CD4<350 having a positive dye test indicating incomplete closure, compared to 2.8% of women with CD4>350 (p=0.024). Conclusion and Global Health Implications: Our analysis confirms previous research indicating that seropositive women with a CD4>350 can safely undergo obstetric fistula repair. Further research is needed to evaluate postoperative outcomes among women with CD4<350. Copyright © 2021 Ganesh et al. Published by Global Health and Education Projects, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution License CC BY 4.0.
9
Brahm, Rafael Ucker, and Roberto Pedroso de Oliveira. "Potencial de multiplicação in vitro de cultivares de morangueiro." Revista Brasileira de Fruticultura 26, no. 3 (December 2004): 507–10. http://dx.doi.org/10.1590/s0100-29452004000300032.
Анотація:
Este trabalho foi realizado com o objetivo de avaliar o potencial de multiplicação in vitro de dez cultivares de morangueiro: Aromas, Bürkley, Camarosa, Campinas, Dover, Milsei-Tudla, Oso Grande, Santa Clara, Sweet Charlie e Vila Nova. Utilizou-se protocolo similar ao dos laboratórios comerciais. A desinfestação dos estolões foi realizada em soluções à base de álcool e hipoclorito de sódio; a cultura dos meristemas em meio semi-sólido MS com 1 mg L-1 BAP, 0,01 mg L-1 ANA e 0,1 mg L-1 AG3; e a multiplicação em meio MS com 1 mg L-1 BAP, à 25 ± 4ºC, 20 µE m-2 s-1 e fotoperíodo de 16 horas. Partiu-se de 10 meristemas de cada cultivar, avaliando-se a taxa de multiplicação e os níveis de contaminação, vitrificação e oxidação durante as fases de estabelecimento (30 dias) e de multiplicação (quatro subcultivos). O número estimado de plântulas obtidas por meristema foi: 559 de 'Aromas'; 569 de 'Bürkley'; 516 de 'Camarosa'; 517 de 'Campinas'; 3.907 de 'Dover'; 1.841 de 'Milsei-Tudla'; 943 de 'Oso Grande'; 350 de 'Santa Clara'; 298 de 'Sweet Charlie', e 1.132 de 'Vila Nova'. A quantificação dessa variabilidade genética é importante para o planejamento da produção de matrizes de cada cultivar nos laboratórios de micropropagação.
10
Endres, S., J. Unger, N. Wannicke, M. Nausch, M. Voss, and A. Engel. "Response of <i>Nodularia spumigena</i> to <i>p</i>CO<sub>2</sub> – Part 2: Exudation and extracellular enzyme activities." Biogeosciences 10, no. 1 (January 29, 2013): 567–82. http://dx.doi.org/10.5194/bg-10-567-2013.
Анотація:
Abstract. The filamentous and diazotrophic cyanobacterium Nodularia spumigena plays a major role in the productivity of the Baltic Sea as it forms extensive blooms regularly. Under phosphorus limiting conditions Nodularia spumigena have a high enzyme affinity for dissolved organic phosphorus (DOP) by production and release of alkaline phosphatase. Additionally, they are able to degrade proteinaceous compounds by expressing the extracellular enzyme leucine aminopeptidase. As atmospheric CO2 concentrations are increasing, we expect marine phytoplankton to experience changes in several environmental parameters, including pH, temperature, and nutrient availability. The aim of this study was to investigate the combined effect of CO2-induced changes in seawater carbonate chemistry and of phosphate deficiency on the exudation of organic matter, and its subsequent recycling by extracellular enzymes in a Nodularia spumigena culture. Batch cultures of Nodularia spumigena were grown for 15 days under aeration with low (180 μatm), medium (380 μatm), and high (780 μatm) CO2 concentrations. Obtained pCO2 levels in the treatments were on median 315, 353, and 548 μatm CO2, respectively. Extracellular enzyme activities as well as changes in organic and inorganic compound concentrations were monitored. CO2 treatment–related effects were identified for cyanobacterial growth, which in turn influenced the concentration of mucinous substances and the recycling of organic matter by extracellular enzymes. Biomass production was increased by 56.5% and 90.7% in the medium and high pCO2 treatment, respectively, compared to the low pCO2 treatment. In total, significantly more mucinous substances accumulated in the high pCO2 treatment, reaching 363 μg Xeq L−1 compared to 269 μg Xeq L−1 in the low pCO2 treatment. However, cell-specific rates did not change. After phosphate depletion, the acquisition of P from DOP by alkaline phosphatase was significantly enhanced. Alkaline phosphatase activities were increased by factor 1.64 and 2.25, respectively, in the medium and high compared to the low pCO2 treatment. We hypothesise from our results that Nodularia spumigena can grow faster under elevated pCO2 by enhancing the recycling of organic matter to acquire nutrients.
11
Kharkhal, H. N., L. P. Titov, and O. O. Yanovich. "Molecular evolution of the meningococcal fragments of 7 house-keeping genes." Proceedings of the National Academy of Sciences of Belarus, Medical series 17, no. 3 (August 29, 2020): 301–19. http://dx.doi.org/10.29235/1814-6023-2020-17-3-301-319.
Анотація:
The objective of the article was to determine the variability of meningococcal house-keeping gene alleles circulating in Belarus. House-keeping genes sequencing was made by Sanger (ABI 3500). The phylogenetic analysis was done in MEGA X. SNPs were analyzed at pubMLST.org. 60 Belarusian meningococci, collected during 8 years, contain 17 alleles of abcZ gene (5.9 % first identified in Belarus – abcZ 1016) encoding 5 variants of the ABC transporter; 16 adk gene alleles – 2 variants of adenylate cyclase; 17 alleles of aroE gene (11.8 % Belarusian – aroE 944 and aroE 972) – 14 variants of shikimat dehydrogenase; 24 alleles of fumC gene (4.2 % Belarusian – fumC 988) – 4 variants of fumarate dehydratase; 18 alleles of gdh gene (16.7 % first identified in Belarus – gdh 560, gdh 985 and gdh 1083) – 4 variants of glucose-6-phosphate dehydrogenase; 18 alleles of pdhC gene – 11 variants of pyruvate dehydrogenase subunit and 20 alleles of pgm gene – 13 variants of phosphoglucomutase (5.6 and 5 % of Belarusian alleles − pdhC 888 and pgm 1099 respectively). Dominant alleles are abcZ 8 – 25 %, adk 5 – 30, aroE 6 – 28.3, fumC 17 – 30, gdh 560 – 20, pdhC 18 – 21.7, pgm 2 – 25 %. The Belarusian meningococcal population is diverse and includes both its own house-keeping gene alleles (7.7 %) and those circulating in other countries (92.3 %). The number of SNPs is varied from 29 (adk) to 125 (aroE). Single nucleotide polymorphisms are mostly synonymous and, on average, lead to amino acid substitutions in the range from 0.6 % in adenylate cyclase and up to 26.4 % in shikimat dehydrogenase.
12
Dolgih, Igor I., Dmitry A. Zhukalin та Larisa A. Bityutskaya. "КОЛЛЕКТИВНАЯ ДИНАМИКА И РАЗМЕРНЫЕ ЭФФЕКТЫ ФАЗООБРАЗОВАНИЯ В СИСТЕМЕ АЭРОСИЛ – ПОЛИСТИРОЛЬНЫЙ ЛАТЕКС". Kondensirovannye sredy i mezhfaznye granitsy = Condensed Matter and Interphases 21, № 3 (26 вересня 2019): 366–73. http://dx.doi.org/10.17308/kcmf.2019.21/1150.
Анотація:
В стандартных условиях проведен модельный эксперимент по влиянию сил обеднения на процесс высыхания капли взвесей невзаимодействующих частиц аэросил – полистирольный латекс. Впервые обнаружен быстропротекающий процесс фазового превращения аэросила в кристаллический SiO2 в течение десятков секунд, сопровождающийся резким изменением цвета раствора от светло-голубого до синего. Обнаружена дифракционная картина, свидетельствующая о нанокристаллической природе зародышеобразования новой фазы. Фазообразование интерпретировано как результат действия неравновесной силы обеднения в условиях гидродинамической неустойчивости высыхающей капли.
REFERENCES
Tret’yakov Yu. D. Self-organisation processes in the chemistry of materials. Uspekhi khimii [Russian Chemical Reviews], 2003, v. 72(8), pp. 651–679. https://doi.org/10.1070/RC2003v072n08ABEH000836
Kushnir S. E., Kazin P. E., Trusov L. A., Tret’yakov Yu. D. Self-organization of micro- and nanoparticles in ferrofl uids. Uspekhi khimii [Russian Chemical Reviews], 2012, v. 81(6), pр. 560–570. https://doi.org/10.1070/RC2012v081n06ABEH004250
Lebedev-Stepanov P. V., Kadushnikov R. M., Molchanov S. P., Ivanov A. A., Mitrokhin V. P., Vlasov K. O., Rubin N. I., Yurasik G. A., Nazarov V. G., Alfi mov M. V. Self-assembly of nanoparticles in the microvolume of colloidal solution: Physics, modeling, and experiment. Rossiiskie nanotekhnologii [Nanotechnologies in Russia], 2013, v. 8(3-4), pр. 137–162. https://doi.org/10.1134/S1995078013020110
Walker D. A., Kowalczyk B., Cruz M. O., Grzybowski B. A. Electrostatics at the nanoscale. Nanoscale, 2011, v. 3(4), pp. 1316–1344. https://doi.org/10.1039/C0NR00698J
Ouyang Q., Castets V., Boissonade J., et al. Sustained patterns in chlorite–iodide reactions in a onedimensional reactor. J. Chem. Phys., 1991, v. 95(1), pp. 351–360. https://doi.org/10.1063/1.461490
Tarasevich Yu. Yu., Pravoslavnova D. M. Kachestvennyy analiz zakonomernostey vysykhaniya kapli mnogokomponentnogo rastvora na tverdoy podlozhke [Qualitative analysis of patterns of drying of a drop of a multicomponent solution on a solid substrate], Zhurnal tekhnicheskoi fi ziki [Technical Physics], 2007, vol. 77, no. 2. pp. 17–21. URL: http://journals.ioffe. ru/articles/viewPDF/9047 (in Russ.)
Faigl’ F., Anger V. Kapel’nyi analiz neorganicheskikh veshchestv [Drip Analysis of Inorganic Substances]. Moscow, Mir Publ., 1976, v. 1, 390 p., v. 2, 320 p. (in Russ.)
Yakhno T. A., Kazakov V. V., Sanina O. A., Sanin A. G., Yakhno V. G. Kapli biologicheskikh zhidkostey, vysykhayushchie na tverdoy podlozhke: dinamika morfologii, massy, temperatury i mekhanicheskikh svoystv [Drops of biological fluids drying on a solid substrate: dynamics of morphology, mass, temperature, and mechanical properties]. Zhurnal tekhnicheskoi fi ziki [Technical Physics], 2010, v. 80(7), pp. 17–23. URL: http://journals.ioffe.ru/articles/viewPDF/10043 (in Russ.)
Alfi mov M. V., Kadushnikov R. M., Shturkin N. A., Alievskii V. M., Lebedev-Stepanov P. V. Immitatsionnoe modelirovanie protsessov samoorganizatsii nanochastits [Simulation modeling of self-organization processes of nanoparticles], Rossiiskie nanotekhnologii [Nanotechnologies in Russia], 2006, v. 1(1–2), pp. 127–133. (in Russ.)
Lebedev-Stepanov P. V., Gromov S. P., Molchanov S. P., Chernyshov N. A., Batalov I. S., Sazonov S. K., Lobova N. A., Shevchenko N. N., Men’shikova A. Yu., Alfimov M. V. Controlling the self-assemblage of modifi ed colloid particle ensembles in solution microdropletsRossiiskie nanotekhnologii [Nanotechnologies in Russia], 2011, v. 6(9–10), 569–578, pp. 72–78. https://doi.org/10.1134/S1995078011050119
Andreeva L. V., Novoselova A. S., Lebedev-Stepanov P. V., Ivanov D. A., Koshkin A. V., Petrov A. N., Alfi mov M. V. Zakonomernosti kristallizatsii rastvorennykh veshchestv iz mikrokapli [Patterns of crystallization of dissolved substances from microdrops]. Zhurnal tekhnicheskoi fi ziki [Technical Physics], 2007, v. 77(2), pp. 22–30. URL: http://journals.ioffe.ru/articles/view-PDF/9048 (in Russ.)
Barash L. Yu. Marangoni convection in an evaporating droplet: Analytical and numerical descriptions. International Journal of Heat and Mass Transfer, 2016, v. 102, pp. 445–454. https://doi.org/10.1016/j.ijh eatmasstransfer.2016.06.042 al
Bityutskaya L. A., Zhukalin D. A., Tuchin A. V., Frolov A. A., Buslov V. A. Thermal dissipative structures in the case of carbon nanotubes aggregation in drying drops. Kondensirovannye sredy i mezhfaznye granitsy [Condensed Matter and Interphase], 2014, v. 16(4), pp. 425–430. URL: https://journals.vsu.ru/kcmf/ article/view/856/937 (in Russ.)
Asakura S., Oosawa F. Interaction between particles suspended in solutions of macromolecules. Polymer Science Part A: General Papers, 1958, v. 33(126), pp. 183–192. https://doi.org/10.1002/pol.1958.1203312618
Minton A. P. How can biochemical reactions within cells differ from those in test tubes? Journal of Cell Science, 2015, v. 119(14), pp. 2863–2869. https://doi.org/10.1242/jcs.03063
Chebotareva N. A., Kurganov B. I., Livanova N. B. Biochemical effects of molecular crowding. Biohimija [Biochemistry], 2004, v. 69(11), pp. 1239–1251. https://doi.org/10.1007/s10541-005-0070-y
Bishop K. J., Wilmer C. E., Soh S., Grzybowski B. A. Nanoscale forces and their uses in self-assembly. Small, 2009, v. 5(14), p. 1600–1630. https://doi.org/10.1002/smll.200900358
Minton A. P. The infl uence of macromolecular crowding and macromolecular confi nement on biochemical reactions in physiological media. Journal of Biological Chemistry, v. 276(14), pp. 10577–10580. https://doi.org/10.1074/jbc.r100005200
Huber F., Strehle D., Schnauss J., Kas J. Formation of regularly spaced networks as a general feature of actin bundle condensation by entropic forces. New J. Physics, 2015, v. 17(4), p. 043029. https://doi.org/10.1088/1367-2630/17/4/043029
Jiang H., Wada H., Yoshinaga N., Sano M. Manipulation of colloids by a nonequilibrium depletion force in a temperature gradient. Physical Review Letters, 2009, v. 102(20), p. 208301. https://doi.org/10.1103/physrevlett.102.208301
Deng H., Li G., Liu H. Assembling of three-dimensional crystals by optical depletion force induced by a single focused laser beam. Optics Express, 2012, v. 20(9), p. 9616. https://doi.org/10.1364/oe.20.009616
Wulfert R., Seiferta U., Speck T. Nonequilibrium depletion interactions in active microrheology. Soft Matter, 2017, v. 13(48), p. 9093–9102. https://doi.org/10.1039/c7sm01737e
Dolgih I. I., Bitutskaya L. A. Entropy driven aggregation of CNT in a drying drop on hydrophilic and hydrophobic substrate. Kondensirovannye sredy i mezhfaznye granitsy [Condensed Matter and Interphase], 2018, v. 20(4), p. 664–668. https://doi.org/10.17308/kcmf.2018.20/635
13
Mannan, Md Abdul, and Ferdousi Begum. "Genetic diversity in maize at germination and seedling stages under simulated drought conditions." Annals of Bangladesh Agriculture 27, no. 2 (December 31, 2023): 19–30. http://dx.doi.org/10.3329/aba.v27i2.72515.
Анотація:
Ninety seven maize (Zea mays) genotypes were evaluated for germination and early seedling characters under PEG6000 (8%) induced drought stress to identify drought tolerant genotypes. Descriptive statistics for percentage of seed germination and abnormal seedling, shoot length, root length, and shoot dry weight, root dry weight, seedling length, seedling dry weight, and vigor index revealed significant variation among the genotypes studied. The percentage of germination and abnormal seedlings varied greatly among the genotypes. The first and second principal components (PC) of PCA results accounted for 73.15 and 26.85% of the total variation of maize genotypes, respectively. The first PC variation consisted primarily of relative seedling shoot dry weight and relative seedling root dry weight. Cluster analysis grouped the genotypes into four clusters. Cluster III genotypes performed better in terms of relative shoot dry weight, relative root dry weight, and number of abnormal seedlings, indicating drought tolerance. Very poorly performance was shown by genotypes in cluster IV, whereas moderately performance was shown by genotypes in cluster II and I. The clusters differed significantly from one another, according to D2 and multivariate analysis. Thirty six genotypes viz. BD-814, BD-810, BD-812, BD-821, BD-815, BD-10015, BD-10238, CML-552, BD-822, BD-826, CML-341, CML-555, CML-591, CML-523, CML-564, BD-817, BD-10018, BD-10240, CML-577, CML-342, CML-556, BD-837, CML-544, BD-827, BD-806, BD-835, BD-840, BD-842, BD-10010, CML-562, BD-10239, BD-10016, CML-593, CML-568 and BD-10234 demonstrated relatively drought tolerance during the germination and early seedling stages might be used in future breeding program. Ann. Bangladesh Agric. (2023) 27 (2): 19-30
14
Weerakoon, Dushni. "Book Reviews : Emerging Asia: Changes And Challenges Asian Development Bank,1997, 350 pp, ISBN 971-561-105-2." South Asia Economic Journal 1, no. 1 (March 2000): 183–87. http://dx.doi.org/10.1177/139156140000100109.
15
Vasconcellos, Vitor Fiorin de, Diogo Assed Bastos, Allan Andresson Lima Pereira, Bruno Rodriguez Pereira, Jamile Almeida Silva, David Queiroz Borges Muniz, Giuliano Guglielmetti, William Carlos Nahas, and Carlos Dzik. "Clinical characteristics and treatment outcomes of patients (pts) with advanced germ cell tumor (aGCT) treated at a tertiary cancer center in Brazil." Journal of Clinical Oncology 36, no. 6_suppl (February 20, 2018): 568. http://dx.doi.org/10.1200/jco.2018.36.6_suppl.568.
Анотація:
568 Background: Reported treatment outcomes for pts with aGCT are largely based on series from developed countries. Data from less developed countries are lacking. Methods: From 2000 to 2015, a retrospective analysis identified 302 pts with aGCT treated at Instituto do Cancer do Estado de São Paulo (ICESP). Kaplan-Meier methods were used for analysis of progression-free survival (PFS) and overall survival (OS) according to the International Germ Cell Consensus Classification Group (IGCCCG). Results: Median follow-up was 46 months and median age was 28 years old. Clinical features and management are detailed in the Table. 54 pts (18%) had ECOG performance status (PS) ≥ 2 at baseline. According to the IGCCCG, 57% were good-, 18.3% intermediate-, and 24.7% poor-risk disease. Median AFP was 2.9, 243, and 3.998 and HCG was 0.4, 113 and 301 in IGCCCG good-, intermediate-, and poor-risk groups, respectively. 5-year PFS and OS were 69% and 85%, respectively, including 83% and 95.3% in good-risk, 70.9% and 83.6% in intermediate-risk and 35.1% and 62.2% in poor-risk pts. Only 3 pts (3%) received high-dose chemotherapy (HDCT) as first salvage therapy. Conclusions: Brazilian pts with advanced GCT in this cohort had similar outcomes as pts in the IGCCCG database. In comparison to contemporary series, pts with intermediate- and poor-risk GCT had slightly inferior PFS and OS, possibly due to a high percentage of pts with poor PS and less use of HDCT. [Table: see text]
16
Atar, Shaul, Yumei Ye, Yu Lin, Sheldon Y. Freeberg, Shawn P. Nishi, Salvatore Rosanio, Ming-He Huang, Barry F. Uretsky, Jose R. Perez-Polo, and Yochai Birnbaum. "Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2." American Journal of Physiology-Heart and Circulatory Physiology 290, no. 5 (May 2006): H1960—H1968. http://dx.doi.org/10.1152/ajpheart.01137.2005.
Анотація:
We determined the effects of cyclooxygenase-1 (COX-1; SC-560), COX-2 (SC-58125), and inducible nitric oxide synthase (iNOS; 1400W) inhibitors on atorvastatin (ATV)-induced myocardial protection and whether iNOS mediates the ATV-induced increases in COX-2. Sprague-Dawley rats received 10 mg ATV·kg−1·day−1 added to drinking water or water alone for 3 days and received intravenous SC-58125, SC-560, 1400W, or vehicle alone. Anesthesia was induced with ketamine and xylazine and maintained with isoflurane. Fifteen minutes after intravenous injection rats underwent 30-min myocardial ischemia followed by 4-h reperfusion [infarct size (IS) protocol], or the hearts were explanted for biochemical analysis and immunoblotting. Left ventricular weight and area at risk (AR) were comparable among groups. ATV reduced IS to 12.7% (SD 3.1) of AR, a reduction of 64% vs. 35.1% (SD 7.6) in the sham-treated group ( P < 0.001). SC-58125 and 1400W attenuated the protective effect without affecting IS in the non-ATV-treated rats. ATV increased calcium-independent NOS (iNOS) [11.9 (SD 0.8) vs. 3.9 (SD 0.1) × 1,000 counts/min; P < 0.001] and COX-2 [46.7 (SD 1.1) vs. 6.5 (SD 1.4) pg/ml of 6-keto-PGF1α; P < 0.001] activity. Both SC-58125 and 1400W attenuated this increase. SC-58125 did not affect iNOS activity, whereas 1400W blocked iNOS activity. COX-2 was S-nitrosylated in ATV-treated but not sham-treated rats or rats pretreated with 1400W. COX-2 immunoprecipitated with iNOS but not with endothelial nitric oxide synthase. We conclude that ATV reduced IS by increasing the activity of iNOS and COX-2, iNOS is upstream to COX-2, and iNOS activates COX-2 by S-nitrosylation. These results are consistent with the hypothesis that preconditioning effects are mediated via PG.
17
Bouligny, Ian, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, and Keri Maher. "CPX-351 Versus FLAG-IDA with or without Venetoclax in Previously Untreated and Relapsed or Refractory Acute Myeloid Leukemia." Blood 142, Supplement 1 (November 28, 2023): 4269. http://dx.doi.org/10.1182/blood-2023-189184.
Анотація:
1. Introduction A recent randomized comparison of liposomal daunorubicin and cytarabine (CPX-351) did not improve response rates or overall survival compared with FLAG-IDA in newly diagnosed acute myeloid leukemia (AML) - although subgroup analyses appeared to show some benefit with CPX-351. The real-world outcomes of these cohorts are unknown. Additionally, there is little data on the relative outcomes of these cohorts in the relapsed or refractory (RR) setting. We aimed to explore the efficacy of CPX-351 and FLAG-IDA with or without venetoclax in newly diagnosed and RR AML outside of clinical trials. 2. Methods We analyzed 142 patients from the Project ERIS database with newly diagnosed or relapsed or refractory (RR) AML treated with CPX-351 or FLAG-IDA from January 1, 2013 to April 18, 2023 at VCU Massey Comprehensive Cancer Center. We recorded baseline patient-related and disease characteristics, including age, ECOG, Charlson comorbidity index (CCI) scores, molecular profiling and ELN 2022 cytogenetic risk, dates of regimen initiation, and survival. We used the D'Agostino & Pearson method for normality testing and the t-test or Mann-Whitney (as applicable) tests for between-group comparisons. Categorical comparisons used Fischer's exact test. We applied the Bonferroni correction if multiple comparisons were made. The Wilson-Brown method was used for 95% confidence intervals. We analyzed survival by the Kaplan-Meier method with significance determined by the log-rank test. The event for calculating the overall survival (OS) was the date of death. Patients were otherwise censored at the date of last contact. 3. Results First, we analyzed 43 (30.3%) patients with newly diagnosed AML fit for intensive chemotherapy: 33 (76.7%) received CPX-351 and 10 (23.3%) received FLAG-IDA. In the FLAG-IDA cohort, three (30.0%) patients received concurrent venetoclax. There were no significant differences in baseline characteristics, including age, sex, race, or CCI scores, shown in Table A. However, patients in the CPX-351 cohort had significantly worse ECOG performance status compared with the FLAG-IDA cohort (median, 1 vs 0, p = 0.007). There were no significant differences in the proportion of patients that had ELN 2022 adverse risk cytogenetics between the CPX-351 and FLAG-IDA cohorts (65.6% vs 55.6%, p = 0.701). The composite complete response rate (CRc; CR + CRi + CRh) was 53.6% (95% CI: 35.8-70.5) in the CPX-351 cohort and 62.5% (95% CI: 30.6-86.3) for FLAG-IDA (p = 0.709). The rate of MRD negativity was 33.3% for CPX-351 (95% CI: 5.9-70.0) and 50.0% (95% CI: 2.6-97.4) for FLAG-IDA. A similar proportion of patients proceeded to allogeneic stem cell transplant (alloSCT; 39.4% vs 40.0%, p > 0.999). There was no significant difference in the median overall survival in patients treated with CPX-351 or FLAG-IDA (16.1 m. vs 11.4 m., p = 0.129, Figure B). Next, we analyzed 96 (90.7%) patients that received FLAG-IDA and ten (9.3%) that received CPX-351 for RR AML in any subsequent line; three (2.1%) patients in the overall cohort received either CPX-351 or FLAG-IDA in the first-line setting, then crossed over to the other arm at disease progression. Sixteen (16.7%) patients received venetoclax with FLAG-IDA. There were no significant baseline differences between cohorts, as shown in Table A. The CRc for CPX-351 was 33.3% (95% CI, 5.9-70.0) compared with 47.7% (95% CI, 37.6-58.0, p = 0.681) for FLAG-IDA. The rate of MRD negativity was 50.0% (95% CI, 2.6-97.4) for CPX-351 and 66.7% for FLAG-IDA (95% CI, 39.1-86.2, p > 0.999). There was no significant difference in the median overall survival in patients treated with CPX-351 or FLAG-IDA (12.7 m. vs 14.5 m., p = 0.561). 4. Discussion There was no significant difference in the rates of CRc, MRD negativity, or overall survival in patients that received CPX-351 or FLAG-IDA with or without venetoclax in the first-line setting or at the time of disease progression. Both approaches appear to be viable in carefully selected cohorts of patients. A comprehensive toxicity analysis and exploratory molecular subgroup analysis are ongoing.
18
Sakata, Tsutomu, Katsunori Makihara, Hidenori Deki, Seiichiro Higashi, and Seiichi Miyazaki. "High Rate Growth of Highly-Crystallized Ge Films on Quartz from VHF Inductively-Coupled Plasma of GeH4 + H2." Materials Science Forum 561-565 (October 2007): 1209–12. http://dx.doi.org/10.4028/www.scientific.net/msf.561-565.1209.
Анотація:
We have studied uniform growth of crystalline Ge films on quartz plate from VHF (60MHz)-ICP of 10% GeH4 diluted with H2 in the temperature range from 150 to 350°C. By optimizing total gas flow rate, gas pressure, VHF power and antenna-substrate distance, the growth rate as high as 7.4nm/s was obtained at 150°C and increased gradually up to ~7.9nm/s at 350°C. The crystallinity, which was evaluated by Raman scattering measurements as an integrated intensity ratio of TO phonons in crystalline phase to those in disordered phase, reached a value as high as ~93 % at 350°C, but degraded down to 64% at 150°C as a result of the formation of a 60~70nm-thick amorphous incubation (A. I.) layer on quartz. By applying a two-step deposition method at 150°C, in which the GeH4 concentration was selected to be 0.6% for the crystalline nucleation in the first 10s deposition, being as thin as 10nm in thickness, and then changed to 10% GeH4 for the high rate growth, the crystallinity was improved to 78% with keeping an effective growth rate as high as 7.5nm/s, because of a significant increase in the growth rate after the crystalline nucleation.
19
Leger, Kasey J., Michael Absalon, Biniyam G. Demissei, Robert B. Gerbing, Todd Allen Alonzo, Betsy A. Hirsch, Jessica Anne Pollard, et al. "Change in cardiac function with CPX-351 in relapsed pediatric AML: A Children’s Oncology Group (COG) report from AAML1421." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 10532. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.10532.
Анотація:
10532 Background: Anthracyclines (AC) are highly effective in treating acute myeloid leukemia (AML), but limited by cardiotoxicity (CTX). CPX-351, a liposomal preparation of daunorubicin (DNR) and cytarabine, may provide therapeutic benefit with less CTX. We evaluated acute changes in cardiovascular (CV) function and biomarkers after 1 cycle of CPX-351 in children with relapsed AML within the phase 1/2 study, AAML1421. Methods: Patients (pts) received 135 units/m2/dose of CPX-351 on days 1, 3, and 5. Echocardiograms were centrally quantified at baseline (BL) and day 29 (end of cycle (EOC)). High sensitivity troponin (cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were measured at BL and days 5, 8, 15, 22, and 29. Differences between BL and post-CPX-351 echo/biomarker measurements were analyzed using pre-specified Wilcoxon signed rank tests. The relationship between EOC ejection fraction (EF) and clinical variables was assessed using repeated measures linear regression. Results: In 32 included pts, the median AC exposure prior to study entry was 337 mg/m2 DNR equivalents. At baseline, markers of CV function and stress were abnormal (Table). Over 1 cycle, there was a statistically significant decrease in EF and circumferential strain (Table). NT-proBNP and cTnT did not increase significantly over time. In multivariable analysis, only increasing body surface area was significantly associated with lower EOC EF (b:-5.9, 95% CI -10.8,-0.9). Cancer therapy–related cardiac dysfunction, defined as ≥10% decline in EF to < 50%, occurred in 6/32 pts at EOC. Conclusions: In this single arm study of AC pre-treated children, baseline abnormalities in CV function were common. CPX-351 was associated with a statistically significant decline in CV function without a rise in cardiac biomarkers. Absent a comparator population, it is not known how these cardiac trends compare to non-liposomal AC or non-AC salvage regimens. The COG AAML1831 trial will determine if CPX-351 offers cardioprotection compared to standard AC in pts with de novo AML. Clinical trial information: NCT02642965. [Table: see text]
20
Petrova, Olga V. "Review of Shlepnyev D.N., 2019. General Theory of Translation: Beginnings. Job Introduction Part II. Nizhny Novgorod: NGLU, 354 p." Russian Journal of Linguistics 23, no. 2 (December 15, 2019): 569–74. http://dx.doi.org/10.22363/2312-9182-2019-23-2-569-574.
21
Worsa, Kidus Temesgen, Beakal Zinab, and Melese Sinaga Teshome. "Dietary Practice among Type 2 Diabetic Ppatients in Southern Ethiopia." International Journal of Endocrinology 2021 (December 27, 2021): 1–9. http://dx.doi.org/10.1155/2021/1359792.
Анотація:
Background. Diabetic patients’ dietary practice is critical to improve glycemic, lipid, and blood pressure control. However, a significant number of patients had poor dietary practice. In Ethiopia, more than half of diabetic patients were not practicing a healthy dietary approach. Therefore, this study assessed variables that were hardly addressed in previous studies. The aim of this study was to assess dietary practice and associated factors among patients with type 2 diabetes. Methods. A facility-based cross-sectional study was performed among patients with type 2 diabetes in Arba Minch General Hospital from April 21 to May 20, 2020. A systematic sampling technique was used to select 352 patients. The data were entered into EpiData version 3.1 and exported to SPSS version 21 for cleaning and analysis. Descriptive statistics were performed. All variables in bivariate analysis with p -value <0.25 were entered into a multivariable logistic regression model, and statistical significance was declared at a p -value of less than 0.05. Results. The prevalence of poor dietary practice was found to be 40.6% (95%CI (35.7–46.0)). After adjusting for other variables in multivariable analysis, not attending formal education (AOR = 3.0; 95%CI (1.6–5.5)), being at primary education level (AOR = 2.2; 95%CI (1.1–4.4)), being moderately food insecure (AOR = 5.3; 95%CI (2.8–9.9)), having depression (AOR = 5.9; 95%CI (3.0–11.4)), and not having nutrition education (AOR = 2.2; 95% (1.1–4.6)) were factors associated with poor dietary practice. Conclusions. A significant proportion of patients had poor dietary practice. The poor dietary practice was significantly higher among those with no formal education, at the primary education level, from the moderately food-insecure household, having depression, and not having nutrition education. The results imply the need for strengthening health information dissemination concerning healthy dietary practice in the form of a package.
22
Yankulova, I., V. Golev, T. Bonev, and K. Jockers. "The Anisotropic Radiation Field in NGC 3516." Symposium - International Astronomical Union 159 (1994): 464. http://dx.doi.org/10.1017/s0074180900176454.
Анотація:
We present new narrow-band images of the Extended Emission-Line Region (EELR) in NGC 3516 in light of [O III] λ 4959, Hα + [N II] λλ 6548, 84, [O I] λ 6364, He is/c λ 6678 and [Fe VII] + [Ca V] λ 6087. The observations were carried with the 2-m reflector of the Bulgarian National Astronomical Observatory and the Focal Reducer of the Max-Plank-Institut for Aeronomy. Our [O III] and Hα + [N II] images confirm previously reported EELR features. In contrast, the image in the high-excitation [Fe VII] + [Ca V] line shows a different structure. We identify a biconical morphology over a kiloparsec scale with peak intensities 5.9 × 10−16 ergs cm−2 s−1 arcsec−2 and 3.5 × 10−16 ergs cm−2 s−1 arcsec−2 to north and south of the nucleus, respectively. The total flux of the [Fe VII] + [Ca V] emission in 5″ and 24″ circular apertures centered at the nucleus is (9.97 ± 0.38) × 10−14 ergs cm−2 s−1 and (1.53 ± 0.15) × 10−13 ergs cm−2 s−1, respectively, which is in good agreement with measurements of Boksenberg & Netzer (1977) through the 5″ aperture. The cone axis lies at PA ∼ −10°. The continuum images (Veilleux et al., 1993, Miyaji et al., 1992) indicate a “bar” aligned along PA ∼ −10°. The velocity extrema regions revealed by Veilleux et al. (1993) are coincident with the peak intensities in our [Fe VII] + [Ca V]. We suppose that our image in [Fe VII] + [Ca V] outlines a Coronal-Line Region (CLR) of NGC 3516, which extends far beyond the classical NLR of the galaxy. Korista & Ferland (1989) have recently shown theoretically that the CLR in Seyferts may be a result of a low-density interstellar medium exposed to and photoionized by a “bare” active nucleus. A typical ISM with Ne ∼ 1–5 cm−3 may produce such an extended CLR as that observed by us.
23
Quinsaat, Jose Enrico Q., Mihaela Alexandru, Frank A. Nüesch, Heinrich Hofmann, Andreas Borgschulte, and Dorina M. Opris. "Highly stretchable dielectric elastomer composites containing high volume fractions of silver nanoparticles." Journal of Materials Chemistry A 3, no. 28 (2015): 14675–85. http://dx.doi.org/10.1039/c5ta03122b.
Анотація:
A composite of Ag/SiO2 core–shell nanoparticles 20 vol% in polydimethylsiloxane with ε′ = 5.9, Eb = 13.4 V μm−1, Y100% = 350 kPa, and a strain at break of 800% is presented.
24
Sharma, Vidit, Kevin M. Wymer, Daniel D. Joyce, James P. Moriarty, Bijan J. Borah, R. Houston Thompson, Brian Addis Costello, Bradley C. Leibovich, and Stephen A. Boorjian. "Cost effectiveness of adjuvant pembrolizumab after nephrectomy for RCC: Insights for patient selection from a Markov model." Journal of Clinical Oncology 40, no. 6_suppl (February 20, 2022): 321. http://dx.doi.org/10.1200/jco.2022.40.6_suppl.321.
Анотація:
321 Background: KEYNOTE-564 demonstrated that adjuvant pembrolizumab after nephrectomy for high-risk clear cell renal cell carcinoma (RCC) decreased the risk of disease progression and – albeit with immature follow-up (2 years) – found a signal of improved overall survival as well. Herein, we used extrapolations from a Markov-model, accounting for the costs and toxicities of pembrolizumab relative to its efficacy, to investigate its utility at a population level. Methods: A decision-analytic Markov Model was used to conduct a cost-utility analysis of adjuvant pembrolizumab versus placebo after nephrectomy for high risk RCC, using data from KEYNOTE-564 to inform model probabilities. Transition probabilities not found in KEYNOTE-564, in addition to utility values, were extracted from the literature. Base case analyses were conducted with 5-year and 15-year time horizons (using extrapolations from 2-year outcomes), and 3-week time cycles. Primary outcomes were Quality-adjusted life years (QALYs), 2021 US Medicare costs, and Incremental cost-effectiveness ratios (ICERs). The willingness-to-pay threshold was set at $100,000/QALY. One-way sensitivity analyses were used to identify cost-effectiveness thresholds of individual parameters while probabilistic sensitivity analyses with 100,000 Monte-Carlo simulations were used to simultaneously vary all model inputs. Results: Pembrolizumab was associated with higher QALYs and costs relative to placebo (Table). Pembrolizumab was not cost-effective at a 5-year time horizon but was cost-effective at 15 years and beyond. One-way sensitivity analysis noted that pembrolizumab became cost-effective at 5-years if: 1) its administration cost was less than $5,064 (base = $10,278) or 2) if the 5-year risk of progression was 18.8% higher in placebo vs pembrolizumab (base = 9%). Using pembrolizumab’s reported hazard ratio of 0.68 for progression from KEYNOTE-564, we estimated that pembrolizumab would be cost-effective at 5-years for all patients with a Mayo Progression Free Survival Score of 10 or higher. Probabilistic sensitivity analysis found that pembrolizumab was cost-effective for 29% and 58% of microsimulations at 5 and 15 years, respectively. Conclusions: At current prices, adjuvant pembrolizumab was not cost-effective for all trial patients at a population level at 5-years after treatment but may be cost-effective for time horizons over 15 years. Instead, adjuvant pembrolizumab was found to be cost-effective only for the highest risk subsets of RCC at 5-years. Longer term trial data of progression-free survival and overall survival are necessary to confirm these extrapolations.[Table: see text]
25
Lin, Tara L., Jorge E. Cortes, Laura F. Newell, Ellen K. Ritchie, Robert K. Stuart, Stephen A. Strickland, Donna Hogge, et al. "The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML." Blood 132, Supplement 1 (November 29, 2018): 2706. http://dx.doi.org/10.1182/blood-2018-99-112557.
Анотація:
Abstract Background: Outcomes for the treatment of AML with conventional induction chemotherapy (eg, 7+3 cytarabine/daunorubicin regimen) are poor for older adults and those with high-risk/secondary AML. CPX-351 (Vyxeos®), a dual-drug liposomal encapsulation of cytarabine and daunorubicin in a synergistic ratio, was approved by the US FDA in 2017 for the treatment of adults with newly diagnosed, therapy-related AML or AML with myelodysplasia-related changes and is currently under review by the EMA. A large randomized, open-label, multicenter, phase 3 study (ClinicalTrials.gov #NCT01696084) evaluated the efficacy and safety of CPX-351 versus conventional 7+3 chemotherapy in adults aged 60-75 y with newly diagnosed, high-risk/secondary AML (Lancet JE, et al. J Clin Oncol. 2018). In this study, CPX-351 significantly improved median overall survival (OS; primary endpoint) versus 7+3 (9.56 vs 5.95 mo; HR = 0.69 [95% CI: 0.52-0.90]; 1-sided P = 0.003), as well as event-free survival (EFS; 2.53 vs 1.31 mo; HR = 0.74 [95% CI: 0.58-0.96]; 2-sided P = 0.021). CPX-351 was also associated with higher rates of complete remission (CR; 37.3% vs 25.6%; 2-sided P = 0.040) and CR or CR with incomplete platelet or neutrophil recovery (CR+CRi; 47.7% vs 33.3%; 2-sided P = 0.016) versus 7+3, which likely contributed to the higher rate of patients undergoing hematopoietic cell transplantation (HCT) with CPX-351 (34.0% vs 25.0%; 2-sided P = 0.098). HCT is a potentially curative therapy, and the higher rate of HCT observed in the CPX-351 arm could therefore have an impact on long-term survival outcomes. To better understand the contribution of HCT and treatment with CPX-351 versus 7+3 to survival, exploratory analyses using a time-dependent proportional hazards model were performed to evaluate survival in patients who underwent HCT and assess the impact of treatment with CPX-351 versus 7+3 on survival independent of HCT status. Methods: Patients were randomized 1:1 to receive up to 2 induction cycles with CPX-351 (100 units/m2 [cytarabine 100 mg/m2 + daunorubicin 44 mg/m2] on Days 1, 3, and 5 [2nd induction: Days 1 and 3]) or 7+3 (cytarabine 100 mg/m2/d continuously for 7 d [2nd induction: 5 d] + daunorubicin 60 mg/m2 on Days 1-3 [2nd induction: Days 1-2]). Patients achieving CR or CRi could receive up to 2 consolidations with CPX-351 (65 units/m2 [cytarabine 65 mg/m2 + daunorubicin 29 mg/m2] on Days 1 and 3) or 5+2 (as in 2nd induction). Patients could receive HCT at the discretion of the treating physician. Results: A total of 309 patients were enrolled in the study (CPX-351: n = 153; 7+3: n = 156), and baseline characteristics were balanced between arms. A total of 52 (34.0%) patients in the CPX-351 arm and 39 (25.0%) in the 7+3 arm underwent HCT; most were 60-69 y of age (CPX-351: 69.2%; 7+3: 84.6%), had ECOG performance status ≤1 (CPX-351: 92.3%; 7+3: 94.9%), and were in CR (CPX-351: 57.7%; 7+3: 48.7%) or CRi (CPX-351: 19.2%; 7+3: 12.8%). Median time to HCT from first study dose was similar with CPX-351 (114.5 d) and 7+3 (113.0 d). Similar to the primary endpoint analysis, median OS landmarked from the time of HCT was significantly improved with CPX-351 versus 7+3 (not reached vs 10.25 mo; HR = 0.46 [95% CI: 0.24-0.89]). Further, in the current exploratory analyses in which HCT was treated as a time-dependent covariate, the HRs remained strongly in favor of CPX-351 versus 7+3 for OS (HR = 0.71) and EFS (HR = 0.74), with the upper bounds of the 95% CIs below 1.0 (Table). These results suggest CPX-351 may be associated with prolonged OS and EFS that is independent of HCT. The adverse event profile of CPX-351 was generally consistent with the known safety profile of conventional 7+3. Grade 3-5 adverse events reported in ≥10% of patients in the CPX-351 or 7+3 cohorts included febrile neutropenia (68.0% vs 70.9%), pneumonia (19.6% vs 14.6%), and hypoxia (13.1% vs 15.2%). Early mortality rates with CPX-351 and 7+3, respectively, were 5.9% and 10.6% at Day 30 and 13.7% and 21.2% at Day 60. Conclusions: Treatment with CPX-351 was associated with significantly longer median OS and EFS, as well as a higher proportion of patients achieving remission and undergoing HCT, compared with conventional 7+3 chemotherapy in this population of older patients with newly diagnosed, high-risk/secondary AML. Further, while it is expected that HCT had a positive impact on survival in this study, exploratory analyses suggest that CPX-351 produced positive OS and EFS outcomes independent of HCT. Disclosures Lin: Jazz Pharmaceuticals: Honoraria. Cortes:Novartis: Consultancy, Research Funding; Daiichi Sankyo: Consultancy, Research Funding; Astellas Pharma: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Arog: Research Funding. Ritchie:NS Pharma: Research Funding; Bristol-Myers Squibb: Research Funding; Incyte: Consultancy, Speakers Bureau; Novartis: Consultancy, Other: Travel, Accommodations, Expenses, Research Funding, Speakers Bureau; ARIAD Pharmaceuticals: Speakers Bureau; Astellas Pharma: Research Funding; Celgene: Consultancy, Other: Travel, Accommodations, Expenses, Speakers Bureau; Pfizer: Consultancy, Research Funding. Stuart:Sunesis Pharmaceuticals: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses, Research Funding; Agios: Research Funding; Astellas: Research Funding; Bayer AG: Research Funding; Celator/Jazz Pharmaceuticals: Research Funding; Incyte: Research Funding. Strickland:Tolero Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees; CTI Biopharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; Baxalta: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Boehringer Ingelheim: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astellas Pharma: Consultancy; Sunesis Pharmaceuticals: Consultancy, Research Funding. Bixby:GlycoMimetics: Research Funding. Kolitz:Magellan Health: Consultancy, Honoraria. Schiller:bluebird bio: Research Funding; Astellas Pharma: Membership on an entity's Board of Directors or advisory committees, Research Funding. Wieduwilt:Leadiant: Research Funding; Reata Pharmaceuticals: Equity Ownership; Merck: Research Funding; Shire: Research Funding; Amgen: Research Funding; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees. Ryan:University of Rochester: Patents & Royalties; AbbVie: Equity Ownership. Ryan:Jazz Pharmaceuticals: Employment, Other: Stock and stock options. Chiarella:Celator/Jazz Pharmaceuticals: Employment, Equity Ownership. Louie:Jazz Pharmaceuticals: Employment, Equity Ownership, Patents & Royalties. Uy:GlycoMimetics: Consultancy; Curis: Consultancy.
26
Bi, Wen Yue, Li Wang, Xin Gang Yu, Xing Dong Zhang, Hong Quan Bao, and Hui Feng Zhao. "Effect of Heat Treatment on Coloration of Ag Doped TiO2-SiO2 Films." Key Engineering Materials 336-338 (April 2007): 1793–95. http://dx.doi.org/10.4028/www.scientific.net/kem.336-338.1793.
Анотація:
Silver doped titania-silica films were fabricated by two-step route of sol-gel method using Ti(OC4H9)4, Si(OC2H5)4 and AgNO3 as the precursor materials. The films were annealed at temperature from 350°C to 560°C for a period of time ranging from 15min to 90 min. Optical properties of the films were characterized by UV-visible spectroscopy and the state of silver in the titania-silica films was investigated by XRD patterns. It was found that the annealing temperature and time have considerably influenced the coloration of the films, and with the increase of annealing temperature the [111] orientation of silver crystal occurred which make the color of silver doped titania-silica films deepened. The coloration stability of the silver doped titania-silica films was also investigated.
27
Wanjara, Priti, Mathieu Brochu, and Mohammad Jahazi. "Electron Beam Freeform Fabrication on Stainless Steel." Materials Science Forum 539-543 (March 2007): 4938–43. http://dx.doi.org/10.4028/www.scientific.net/msf.539-543.4938.
Анотація:
The use of electron beam technology for freeforming 321 SS was investigated using 347 SS solid wire and BNi-2 brazing paste as filler materials. The electron beam freeforming (EBFF) studies involved examining the effect of processing parameters on the characteristics of the line build-ups. Specifically, the effective growth rate and the dimensional features (height-to-width ratio) of the build-ups were found to be dependent on the beam energy and the filler material conditions (e.g. wire feed rate and the number of re-melting passes). The EBFF work indicated that build-ups with either filler material could be deposited on 321 SS using an optimized processing window that resulted in properties comparable to technical data available for 347 SS and BNi-2.
28
Yamazaki, Takahiro, Erik Wennerberg, Michal Hensler, Aitziber Buqué Martinez, Jeffrey Kraynak, Jitka Fucikova, Xi Zhou, et al. "560 Immunotherapeutic and antimetastatic activity of LTX-315 in preclinical models of ICI-resistant breast cancer." Journal for ImmunoTherapy of Cancer 9, Suppl 2 (November 2021): A589. http://dx.doi.org/10.1136/jitc-2021-sitc2021.560.
Анотація:
BackgroundOncolytic peptides are attractive tools for the development of novel anticancer regimens [1]. LTX-315 is a synthetic peptide with a marked capacity to elicit tumor-targeting immunity in preclinical cancer models [2]. Indeed, LTX-315 has been shown to elicit immunogenic cell death (ICD) in malignant cells [3, 4] and to deplete immunosuppressive cells such as CD4+CD25+FOXP3+ TREG cells and myeloid-derived suppressor cells (MDSCs) from the tumor microenvironment (TME) [5]. Accordingly, LTX-315 synergized with immunogenic chemotherapeutics or immune checkpoint inhibitors (ICIs) in preclinical tumor models [5, 6]. Moreover, recent findings from a Phase I clinical trial in patients with advanced solid tumors (NCT01986426) indicate that intratumoral LTX-315 is safe, clinically active, and elicits alterations in the TME that support the initiation of anticancer immunity [7, 8]. However, the dependency of LTX-315 therapeutic effects on the immune system in preclinical models of breast cancer has not been mechanistically investigated.MethodsWe harnessed three distinct mouse models of ICI-resistant breast cancer, namely hormone receptor (HR)-positive TS/A established and triple-negative breast cancer (TNBC) 4T1 cells established in immunocompetent syngeneic BALB/c mice, as well as medroxyprogesterone acetate (MPA, M)-initiated, 7,12-dimethylbenz[a]anthracene (DMBA, D)-driven mammary carcinomas evolving in C57BL/6 mice to assess the immunotherapeutic effects of LTX-315 optionally combined with radiation therapy (RT), based on the primary tumor growth, metastatic dissemination and overall survival (depending on model). Multilesion models, rechallenge assays, antibody-mediated depletion experiments as well as experiments in Rag1-/- mice were employed to elucidate the mechanistic involvement of the immune system.ResultsIn the multilesion TS/A models, intratumoral LTX-315 to one lesion combined with hypofractionated RT to another lesion resulted in superior systemic disease control as manifested by eradication of a 3rd untreated lesion in up to 50% of mice, which were protected from a subsequent rechallenge with living TS/A cells. In the single lesion 4T1 model, LTX-315 mediated enable robust local and metastatic disease control, which could be enhanced (only locally) with RT and dependent on natural killer (NK) cells, but less so on T lymphocytes (as determined with anti-asialo GM1 antibodies and Rag1-/- hosts). In the M/D-driven model, LTX-315 considerably controlled the growth of primary tumors and delayed relapse, an effect that depended on NK cells (as demonstrated with anti-NK1.1 antibodies).ConclusionsLTX-315, alone and combined with RT, mediates robust immunotherapeutic effects in multiple models of ICI-resistant breast cancer. Intriguingly, NK cells appear to be required for such effects, potentially linked to the emergence of immunological memory.AcknowledgementsWe are indebted to Dr. Fred Miller (Karmanos Cancer Center, Detroit, MI) for the kind gift of 4T1 cells, as well as to Dr. Karsten A. Pilones (Weill Cornell Medicine, New York, NY) and Maria E. Rodriguez-Ruiz (University of Navarra, Pamplona, Spain) for help with clonogenic assays. This work has been sponsored by a research grant by Lytix Biopharma (Oslo, Norway) to S.D. and L.G.ReferencesKepp, O. et al. (2020) Oncolysis without viruses - inducing systemic anticancer immune responses with local therapies. Nat Rev Clin Oncol 17 (1), 49–64.Vitale, I. et al. (2021) Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides. Trends Cancer 7 (6), 557–572.Eike, L.M. et al. (2015) The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells. Oncotarget 6 (33), 34910–23.Zhou, H. et al. (2016) The oncolytic peptide LTX-315 triggers immunogenic cell death. Cell Death Dis 7 (3), e2134.Yamazaki, T. et al. (2016) The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade. Cell Death Differ 23 (6), 1004–15.Camilio, K.A. et al. (2019) Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model. Breast Cancer Res 21 (1), 9.Jebsen, N.L. et al. (2019) Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report. J Med Case Rep 13 (1), 177.Spicer, J. et al. (2021) Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors. Clin Cancer Res 27 (10), 2755–2763.Ethics ApprovalThis study was approved by Weill Cornell Medical College’s Ethics Board; approval number 2015-0028, 2018-0002.
29
Fisk, Geoff. "Object Relations Brief Therapy – The Therapeutic Relationship in Short-Term Work By M. Stadter. Northwale, NJ: Jason Aronson. 1996. 351 pp. £39.95. ISBN 1-568-21660-2." British Journal of Psychiatry 171, no. 6 (December 1997): 593–94. http://dx.doi.org/10.1192/s0007125000148986.
30
Aliev, Amil R., Isa R. Akhmedov, Murad G. Kakagasanov та Zakir A. Aliev. "ПРЕДПЕРЕХОДНЫЕ ЯВЛЕНИЯ В ОБЛАСТИ СТРУКТУРНОГО ФАЗОВОГО ПЕРЕХОДА В СУЛЬФАТЕ КАЛИЯ". Kondensirovannye sredy i mezhfaznye granitsy = Condensed Matter and Interphases 21, № 3 (26 вересня 2019): 350–57. http://dx.doi.org/10.17308/kcmf.2019.21/1148.
Анотація:
Методами спектроскопии комбинационного рассеяния света исследованы структурно-динамические свойства и процессы молекулярной релаксации в кристаллическом сульфате калия K2SO4 в интервале температур от 293 до 900 К. Проанализированы температурные зависимости положения максимума v (частоты), ширины w и интенсивности I спектральной полосы, отвечающей полносимметричному колебанию v1(A) сульфат-иона SO4 2–, в спектральном интервале от 963 до 976 см–1. С ростом температуры частота колебания уменьшается. Примерно при 650 K имеют место определённые особенности температурной зависимости v(T). При дальнейшем увеличении температуры частота продолжает уменьшаться. В точке структурного фазового перехода первого рода (Ts = 854 K)уменьшение частоты приостанавливается. С ростом температуры ширина возрастает, а интенсивность уменьшается. Примерно при 650 K имеют место определённые особенности температурных зависимостей w(T) и I(T). Уменьшение интенсивности приостанавливается, и в интервале температур 650–850 K интенсивность остаётся почти постоянной. При структурном фазовом переходе первого рода (Ts = 854 K) интенсивность уменьшается. Рост ширины при температуре T ≈ 650 K приостанавливается, а затем снова ширина начинает увеличиваться. Ближе к структурному фазовому переходу первого рода (Ts = 854 K) рост ширины замедляется и в точке структурного фазового перехода первого рода (Ts = 854 K) имеет место уменьшение ширины. Установлено, что в кристаллическом сульфате калия K2SO4 структурный фазовый переход первого рода носит растянутый характер. При температуре фазового перехода (Ts = 854 К) ширина резко возрастает, а частота резко уменьшается, уменьшаясь и при дальнейшем увеличении температуры. Обнаружено существование предпереходной области в исследованном кристаллическом сульфате калия K2SO4. Эта предпереходная область имеет место в интервале температур от 650 К до Ts = 854 К.
REFERENCES
Ivanova E. S., Petrzhik E. A., Gainutdinov R. V., Lashkova A. K., Volk T. R. Fatigue processes in triglycine sulfate and the effect of a magnetic fi eld on them. Phys. Solid State, 2017, vol. 59(3), ph. 569–574. https://doi.org/10.1134/S1063783417030155
Aliev A. R., Akhmedov I. R., Kakagasanov M. G., Aliev Z. A., Gafurov M. M., Rabadanov K. Sh., Amirov A. M. Inelastic intermolecular exchange of vibrational quanta and relaxation of vibrationally excited states in solid binary systems. Phys. Solid State, 2017, vo l . 59(4), pp. 752–757. https://doi.org/10.1134/10.1134/S1063783417040035
Bondarev V. S., Mikhaleva E. A., Flerov I. N., Gorev M. V. Electrocaloric effect in triglycine sulfate under equilibrium and nonequilibrium thermodynamic conditions. Phys. Solid State, 2017, vol. 59(6), pp. 1118–1126. https://doi.org/10.1134/S1063783417060051
Aliev A. R., Akhmedov I. R., Kakagasanov M. G., Aliev Z. A., Gafurov M. M., Rabadanov K. Sh., Amirov A. M. Relaxation of vibrationally excited states insolid binary systems “carbonate – sulfate”. Phys. Solid State, 2018, vol. 60(2), pp. 347–351. https://doi.org/10.1134/S1063783418020038
Nguyen Hoai Thu’o’ng, Sidorkin A. S., Milovidova S. D. Dispersion of dielectric permittivity in a nanocrystallinecellulose–triglycine sulfate composite at low and ultralow frequencies. Phys. Solid State, 2018, vo l . 60(3), pp. 559–565. https://doi.org/10.1134/S1063783418030320
Aliev A. R., Akhmedov I. R., Kakagasanov M. G., Aliev Z. A., Gafurov M. M., Rabadanov K. Sh., Amirov A. M. Vibrational relaxation in LiNO3 – LiClO4, Na2CO3 – Na2SO4, and KNO3 – KNO2 solid binary systems. Rus. J. Phys. Chem. B, 2018, vol. 12(3), pp. 357–362. https://doi.org/10.1134/S1990793118030211
Mikhaleva E. A., Flerov I. N., Kartashev A. V., Gorev M. V., Molokeev M. S., Korotkov L. N., Rysiakiewicz-Pasek E. Specifi c heat and thermal expansion of triglycine sulfate–porous glass nanocomposites. Phys. Solid State, 2018, vol. 60(7), pp. 1338–1343. https://doi.org/10.1134/S1063783418070181
Korabel’nikov D. V., Zhuravlev Yu. N. Ab initio structure and vibration properties of oxyanionic crystalline hydrates. Phys. Solid State, 2018, vol. 60(10), pp. 2058-2065. https://doi.org/10.1134/S106378341810013X
Koposov G. D., Bardyug D. Yu. Analysis of ice premelting in water-containing disperse media. Tech. Phys. Lett., 2007, vol. 33(7), pp. 622–624. https://doi.org/10.1134/S1063785007070243
Demikhov E. I., Dolganov V. K. Pretransitional effects near blue phases of a cholesteric liquid crystal. JETP Lett., 1983, vol. 38(8), pp. 445–447. (in Russ.)
Kizel’ V. A., Panin S. I. Pretransition phenomena in cholesterics with a short helix pitch. JETP Lett., 1986, vol. 44(2), pp. 93–96. (in Russ.)
Klopotov A. A., Chekalkin T. L., Gyunter V. E. Effect of preliminary deformation on the fi ne structure of a TiNi-based alloy in the premartensitic region. Tech. Phys., 2001, vol. 46(6), pp. 770–772. https://doi.org/10.1134/1.1379650
Grishkov V. N., Lotkov A. I., Dubinin S. F., Teploukhov S.G., Parkhomenko V.D. Short-wavelength atomic-displacement modulation preceding the B2 →B19’ martensitic transformation in a TiNi-based alloy. Phys. Solid State, 2004, vol. 46(8), pp. 1386–1393. https://doi.org/10.1134/1.1788767
Mel’nikova S. V., Isaenko L. I., Pashkov V. M., Pevnev I. V. Phase transition in a KPb2Br5 crystal. Phys. Solid State, 2005, vol. 47(2), pp. 332–336. https://doi.org/10.1134/1.1866415
Mel’nikova S. V., Fokina V. D., Laptash N. M. Phase transitions in oxyfl uoride (NH4)2WO2F4. Phys. Solid State, 2006, vol. 48(1), pp. 117–121. https://doi.org/10.1134/S1063783406010239
Mel’nikova S. V., Isaenko L. I., Pashkov V. M., Pevnev I. V. Search for and study of phase transitions in some representatives of the APb2X5 family. Phys. Solid State, 2006, vol. 48(11), pp. 2152–2156. https://doi.org/10.1134/S1063783406110217
Mel’nikova S. V., Laptash N. M., Aleksandrov K. S. Optical studies of phase transitions in oxyfl uoride (NH4)2NbOF5. Phys. Solid State, 2010, vol. 52(10), pp. 2168–2172. https://doi.org/10.1134/S1063783410100240
Slyadnikov E. E. Pretransition state and structural transition in a deformed crystal. Phys. Solid State, 2004, vol. 46(6), pp. 1095–1100. https://doi.org/10.1134/1.1767251
Belyaev A. P., Rubets V. P., Antipov V. V. Infl uence of temperature on the rhombic shape of paracetamol molecular crystals. Technical Physics, 2017, vol. 62(4), pp. 645-647. https://doi.org/10.1134/S1063784217040041
Aliev A. R., Gafurov M. M., Akhmedov I. R., Kakagasanov M.G., Aliev Z.A. Structural phase transition peculiarities in ion-molecular perchlorate crystals. Phys. Solid State, 2018, vol. 60(6), pp. 1203–1213. https://doi.org/10.1134/S1063783418060045
Maksimov V. I., Maksimova E. N., Surkova T. P., Vokhmyanin A. P. On possible states of the crystal structure preceding to a phase transition in Zn1–xVxSe (0.01 ≤ x ≤ 0.10) crystals. Phys. Solid State, 2018, vol . 60(12), pp. 2424–2435. https://doi.org/10.1134/S1063783419010177
Vtyurin A. N., Bulou A., Krylov A. S., Afanas’ev M. L., Shebanin A. P. The cubic-to-monoclinic phase transition in (NH4)3ScF6 cryolite: A Raman scattering study. Phys. Solid State, 2001, vol. 43(12), pp. 2307–2310. https://doi.org/10.1134/1.1427961
Karpov S. V., Shultin A. A. Orientational melting and pretransition in ordered phases of rubidium and cesium nitrates. Sov. Phys. Solid State, 1975, vol. 17(10), pp. 1915–1919. (in Russ.)
Gafurov M. M., Aliev A. R., Akhmedov I. R. Raman and infrared study of the crystals with molecular anions in the region of the solid – liquid phase transition. Spectrochim. Acta, 2002, vol. 58A(12), pp. 2683–2692. https://doi.org/10.1016/S1386-1425(02)00014-8
Gafurov M. M., Aliev A. R. Molecular relaxation processes in the salt systems containing anions of various configurations. Spectrochim. Acta, 2004, vol. 60A(7), pp. 1549–1555. https://doi.org/10.1016/j.saa.2003.06.004
Chemical Encyclopedy. V. 2. Moscow, Sov. Entsiklopediya, 1990, p. 289 (in Russ.)
Bale C. W., Pelton A. D. Coupled phase diagram and thermodynamic analysis of the 18 binary systems formed among Li2CO3, K2CO3, Na2CO3, LiOH, KOH, NaOH, Li2SO4, K2SO4 and Na2SO4. CALPHAD, 1982, vol. 6(4), pз. 255–278. https://doi.org/10.1016/0364-5916(82)90020-7
Dessureault Y., Sangster J., Pelton A. D. Coupledphase diagram / thermodynamic analysis of the ninecommon-ion binary systems involving the carbonates and sulfates of lithium, sodium, and potassium. J. Electrochem. Soc., 1990, vol. 137(9), pр. 2941–2950. https://doi.org/10.1149/1.2087103
Lindberg D., Backman R., Chartrand P. Thermodynamic evaluation and optimization of the (Na2CO3 + Na2SO4 + Na2S + K2CO3 + K2SO4 + K2S) system. J. Chem. Thermodynamics, 2007, vol. 39, pp. 942–960. https://doi.org/10.1016/j.jct.2006.11.002
Aliev A. R., Akhmedov I. R., Kakagasanov M. G., Aliev Z. A., Gafurov M. M., Rabadanov K. Sh., Amirov A. M. Relaxation of vibrationally excited states in solid “nitrate – nitrite” binary systems. Opt. Spectrosc., 2017, vol. 123(4), pp. 587–589. https://doi.org/10.1134/S0030400X17100022
31
Kelley, Robin Kate, Mariam Rodriguez Lee, Jimmy Hwang, John Dozier Gordan, Halla Sayed Nimeiri, Andrea Grace Bocobo, Sheetal Mehta Kircher, et al. "Detection of circulating tumor cells (CTC) using a non-EpCAM-based, high-definition, single-cell assay in advanced hepatocellular carcinoma (HCC) for patients enrolled on phase I and II trials of sorafenib plus temsirolimus." Journal of Clinical Oncology 35, no. 4_suppl (February 1, 2017): 311. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.311.
Анотація:
311 Background: Noninvasive biomarkers are needed for diagnosis, prognosis, and molecular profiling of HCC due to scarcity of tumor tissue and heterogeneous tumor biology. CTC are detectable in metastatic HCC using methods which enrich for expression of the cell adhesion molecule, EpCAM. Because a subset of HCC does not express EpCAM, however, non-EpCAM enrichment methods are needed for CTC studies in HCC. Methods: This CTC cohort was derived from patients enrolled on multicenter phase 1 and 2 trials of the combination of sorafenib plus temsirolimus in advanced HCC (NCT01008917, NCT01687673) with approval and funding from the National Comprehensive Cancer Network (NCCN) Oncology Research Program. Eligibility required histologic diagnosis of incurable HCC with no prior systemic therapy. All patients in the cohort were treated at the recommended phase 2 dose of sorafenib 200 mg PO BID and temsirolimus 10 mg IV weekly. Whole blood samples were collected at baseline and on treatment. CTC were enumerated and analyzed cytomorphologically using a high-definition, single cell assay without EpCAM enrichment and blinded to clinical outcomes. Results: The CTC cohort was comprised of 36 patients (phase 1 n = 9, phase 2 n = 27). Characteristics: male 89%; white 64%, Asian/PI 28%, black 6%; HBsAg+ 31%, HCV+ 44%; Child Pugh A 92%, B7 8%; BCLC C 83%; tumor vascular invasion 47%; median AFP 74 ng/mL. Median OS from start of treatment was 392 days (95% CI: 214, 569). CTC ≥ 1/mL were detectable at baseline in 23/36 (64%) overall (95% CI: 47%, 80%), with similar findings in the phase 1 (56%) and phase 2 (67%) subsets. There was no significant relationship between baseline CTC values ≥ 1, 2, or 5/mL and overall survival (OS) on univariate analysis. Analyses of CTC relationship to clinical characteristics and time to progression, changes on treatment, and multivariable analysis for relationship to OS will be presented. Conclusions: CTC were detected in over 60% of patients in this advanced HCC clinical trial cohort using a non-EpCAM, high-definition single cell assay, suggesting future potential for noninvasive molecular profiling of HCC.
32
Redman, Paul B., and John M. Dole. "350 VASE-LIFE DETERMINATION OF SIX SPECIALTY CUT FLOWER SPECIES." HortScience 29, no. 5 (May 1994): 480g—481. http://dx.doi.org/10.21273/hortsci.29.5.480g.
Анотація:
The postharvest attributes of six specialty cut flower species were studied. First year results indicate that Achillea filipendulina `Coronation Gold' had a vase-life of 10.7 days in deionized water (DI) and can be stored one week at 1.7°C and shipped for one day. Buddeleia davidii (Butterfly Bush) had a vase life of 3.8 days in DI water and tolerated two weeks of cold storage and two days of shipping. Celosia plumosa `Forest Fire' (Plume Celosia) had a vase-life of 5.9 days in DI water and tolerated 2 days of shipping. Cercis canadensis (Redbud) had a vase-life of 9 days in DI water and tolerated one day of shipping. Echinacea purpurea `Bright Star' (Purple Coneflower) had a vase-life of 4.6 days in DI water and tolerated 2 weeks of storage and five days of shipping. Helianthus maximilianii (Maximillian Sunflower) had a vase-life of 6.3 days in DI water and tolerated one week of storage. In addition, silver thiosulfate and 8-hydroxyquinoline citrate increased vase-life of Buddeleia davidii, Celosia plumosa, Echinacea purpurea, and Helianthus maximilianii.
33
Ma, Guang Hui, Fa Ai Zhang, and Chang Sheng Gu. "Preparation of Polymer Microspheres Using Silane Coupling Agent Modified Nano-SiO2 as Single Stabilizer." Advanced Materials Research 341-342 (September 2011): 247–51. http://dx.doi.org/10.4028/www.scientific.net/amr.341-342.247.
Анотація:
This paper demonstrates that silica nanoparticles were modified by the four silane coupling agents (KH-151, KH-550, KH-560, KH-570) firstly, then polystyrene/silica (PS/SiO2) composite microsphere with PS core and silica nanoparticles shell were prepared by Pickering emulsion polymerization. The characterization of optical microscope (OM), scanning electron microscope (SEM), and thermogravimetic analysis ( TGA) illustrates that these microsphere are composed of PS and silica nanoparticles. Silica nanoparticles modified by the different silane coupling agents could form the stable PS/SiO2 microsphere over 70 °C, while the unmodified silica nanoparticles are difficult to form stable PS/SiO2 microspheres at the same temperature. The PS/KH-151-SiO2 microsphere exhibits the least average particle size, while the PS/KH-570-SiO2 microsphere produces the largest. Both SEM and TGA confirm that microsphere surface exists solid nanoparticles.
34
Wu, T. Y., та Y. C. Chang. "Hydrodynamic and pharmacological characterization of putative α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/kainate-sensitive l-glutamate receptors solubilized from pig brain". Biochemical Journal 300, № 2 (1 червня 1994): 365–71. http://dx.doi.org/10.1042/bj3000365.
Анотація:
L-[3H]Glutamate binding sites with characteristics resembling that of membrane-bound alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate-subtype L-glutamate receptors have been solubilized from pig brain synaptic junctions by Triton X-114. Binding of [3H]AMPA to these soluble sites in the presence of KSCN results in a curvilinear Scatchard plot that can be resolved into a high-affinity component and a low-affinity component. These Triton-X-114-solubilized sites can be further separated into two species of binding sites by gel-filtration chromatography or sucrose-density-gradient centrifugation. The pharmacological profiles of these two species of binding site are almost identical, and the rank orders of potency for glutamatergic drugs in displacing L-[3H]glutamate binding to these sites are quisqualate > 6,7-dinitroquinoxaline-2,3-dione > 6-cyano-7-nitroquinoxaline-2,3-dione > AMPA > L-glutamate > kainate >> N-methyl-D-aspartate = L-2-amino-4-phosphonobutyrate. Both sites are found to bind [3H]AMPA, and in the presence of KSCN the binding activities are significantly enhanced. Analysis of the hydrodynamic behaviour of these binding sites by sucrose-density-gradient centrifugation in H2O- and 2H2O-based solvents and gel-filtration chromatography has revealed that one of these sites (Stokes radius 8.3 nm, sedimentation coefficient 18.5 S) consists of 562 kDa protein and 281 kDa detergent, and the other site (Stokes radius 9.6 nm, sedimentation coefficient 13.4 S) consists of 352 kDa protein and 569 kDa detergent. Frictional coefficients of these sites indicate that these receptor-detergent complexes are asymmetrical in structure, consistent with large transmembrane proteins.
35
Andre Pupung Darmawan, Angga Erlando, and Dwi Budi Santoso. "Examining an Islamic Financial Inclusivity and Its Impact on Fundamental Economic Variables in Indonesia (An Approach of Static Panel Data Analysis)." Jurnal Ekonomi Syariah Teori dan Terapan 10, no. 4 (July 31, 2023): 337–51. http://dx.doi.org/10.20473/vol10iss20234pp337-351.
Анотація:
ABSTRACT Previous studies mostly measured sharia financial inclusion using an index consisting of three dimensions: accessibility, availability, and usage. This research develops it by adding a digitalization dimension so that there are 4 dimensions in measuring sharia financial inclusion in Indonesia using an index. The first objective of this study is to visually illustrate the results of calculating the sharia financial inclusion index (in map form) in 33 provinces in Indonesia, using GeoDa software. Second, analyze the impact of sharia financial inclusion variables (the 4 form dimensions) that are calculated, on economic fundamental variables (growth, unemployment, poverty, and inequality) through a quantitative approach based on panel data analysis methods (FEM and REM). The secondary data used comes from the Financial Services Authority (OJK) and the Central Statistics Agency (BPS), in the 2015-2020 period. The results of this study indicate that sharia financial inclusion in Indonesia needs to be increased more evenly, so that it is not stagnant and centered in Java or provinces with a communal Muslim base (viewed from the results of index calculations) because the values are unequal between provinces. Meanwhile, the results of panel data analysis techniques show that variables reflecting the 4 dimensions of sharia financial inclusion have an impact on fundamental economic variables. Keywords: Sharia Financial Inclusion, Index, GeoDa, Panel data ABSTRAK Kajian sebelumnya banyak mengukur inklusi keuangan syariah dengan menggunakan indeks yang terdiri dari tiga dimensi: aksessibilitas, availabilitas, dan penggunaan. Penelitian ini mengembangkannya dengan menambah dimensi digitalisasi, sehingga terdapat 4 dimensi dalam mengukur inklusi keuangan syariah di Indonesia menggunakan indeks. Tujuan pertama penelitian ini menggambarkan visual hasil perhitungan indeks inklusi keuangan syariah (dalam bentuk peta) di 33 provinsi yang ada di Indonesia, dengan software GeoDa. Kedua, menganalisis pengaruh variabel inklusi keuangan syariah (4 dimensi pembentuknya) yang dihitung, terhadap variabel fundamental ekonomi (pertumbuhan, tingkat pengangguran, kemiskinan, dan ketimpangan) melalui pendekatan kuantitatif berbasis metode analisis data panel (FEM dan REM). Data yang digunakan bersumber dari Otoritas Jasa Keuangan (OJK) dan Badan Pusat Statistika (BPS), dalam periode 2015-2020. Hasil penelitian ini, menunjukkan bahwa bahwa inklusi keuangan syariah di Indonesia perlu ditingkatkan lebih merata, agar tidak stagnan terpusat di Java atau provinsi dengan basis muslim komunal, jika dilihat dari hasil perhitungan indeks yang nilainya timpang antar porvinsi. Sementara itu, hasil teknik analisis data panel menunjukkan bahwa variabel yang mencerminkan 4 dimensi inklusi keuangan syariah berdampak bagi variabel fundamental ekonomi. Kata Kunci: Inklusi Keuangan Sharia, Indeks, Geoda, Data Panel. REFERENCES Allen, J., Cars, G., & Madanipour, A. (2012). Social exclusion in European cities: processes, experiences and responses. London: Routledge. Alshyab, N., Sandri, S., & Daradkah, D. (2021). The effect of financial inclusion on unemployment reduction-evidence from non-oil producing Arab countries. International Journal of Business Performance Management, 22(2-3), 100-116. Amakor, I. C., & Eneh, O. (2021). Financial inclusion and unemployment rate in Nigeria. International Journal of Research (IJR), 8(11), 1-14. Ananzeh, I. E. N. (2016). Relationship between bank credit and economic growth: Evidence in Jordan. International Journal of Financial Research, 7(2), 53-63. doi:10.5430/ijfr.v7n2p53 Anwar, K., & Amri, A. (2017). Pengaruh inklusi keuangan terhadap PDB Indonesia. Jurnal Ilmiah Mahasiswa Ekonomi Pembangunan, 2(3), 454-462. Arsyad, L. (2014). Konsep dan pengukuran pembangunan ekonomi. Modul Lincolin Arsyad, 1-46. Bansal, S. (2014). Perspective of technology in achieving financial inclusion in rural India. Procedia Economics and Finance, 11, 472-480. Demirgüç-Kunt, A., Beck, T. H. L., & Honohan, P. (2008). Finance for all? Policies and pitfalls in expanding access (No. aec73d3a-d6eb-457f-9182-3946fd15f0bc). Tilburg: Tilburg University, School of Economics and Management. Dienillah, A. A., & Anggraeni, L. (2016). Dampak inklusi keuangan terhadap stabilitas sistem keuangan di Asia. BMEB: Bulletin of Monetery Economics and Banking, 18(4), 409-430. doi:10.21098/bemp.v18i4.574 Fauzan, I. F. (2020). Determinan inklusi keuangan di Indonesia dengan pendekatan panel spasial. Disertasi. Program Doktoral IPB University. Bogor. Fosu, S. B., & Hampshire, N. (2013). Financial development and economic growth in Africa: A dynamic causal relationship. Thesis. The Degree of Master of Arts in Economics University of New Hampshire. Durham. Gupta, A., Chotia, V., & Rao, N. M. (2014). Financial inclusion and human development: A state-wise analysis from India. International Journal of Economics, Commerce and Management, 2(5), 1-23. Gurley, J. G., dan Shaw E. S. (1955). Financial aspects of economic development. The American Economic Review, 45(4), 515–538. Honohan, P. (2004). Financial development, growth and poverty: How close are the links? In E. C. Goodhard, ed., Financial development and economic growth: Explaining the links. London: Palgrave. Honohan, P. (2008). Cross-country variation in household access to financial services. Journal of Banking & Finance, 32(11), 2493-2500. doi:10.1016/j.jbankfin.2008.05.004 Ka’abi, M. S. (2020). Relevansi pemikiran ekonomi muhammad baqir as-sadr dalam keadilan distribusi beras di Indonesia. Skripsi. Program Sarjana Program Studi Ekonomi Syari;ah Institut Agama Islam Negeri Jember. Jember. Kim, D. W., Yu, J. S., & Hassan, M. K. (2018). Financial inclusion and economic growth in OIC countries. Research in International Business and Finance, 43, 1-14. doi:10.1016/j.ribaf.2017.07.178 Lakshmi, P., & Visalakshmi, S. (2013). Impact of cooperatives in financial inclusion & comprehensive development. Journal of Finance and Economics, 1(3), 49-53. doi:10.12691/jfe-1-3-4 Leyshon, A., & Thrift, N. (1995). Geographies of financial exclusion: financial abandonment in Britain and the United States. Transactions of the Institute of British Geographers, 20(3), 312-341. doi:doi.org/10.2307/622654 Lucas, R. E. (1988). On the mechanics of economic development. Journal Of Monetary Economics, 22(1), 3-42. doi:10.1016/0304-3932(88)90168-7 Luo, J., & Li, B. Z. (2022). Impact of digital financial inclusion on consumption inequality in China. Social Indicators Research, 163(2), 529-553. doi:10.1007/s11205-022-02909-6 Masnita, Y., Triyowati, H., & Khomsiyah, K. (2020). Pemberdayaan lembaga keuangan syariah dalam meningkatkan peran inklusi keuangan. JUARA: Jurnal Wahana Abdimas Sejahtera, 1(1), 26-37. doi:10.25105/juara.v1i1.5911 McKinnon, R. I. (1973). Money and capital in economic development. Washington, DC: Brookings Institution. Mehry, E. B., Ashraf, S., & Marwa, E. (2021). The impact of financial inclusion on unemployment rate in developing countries. International Journal of Economics and Financial Issues, 11(1), 79-93. doi:10.32479/ijefi.10871 Miller, M. H. (1988). Financial markets and economic growth. Journal of Applied Corporate Finance, 11(5):8−15. doi:10.1111/j.1745-6622.1998.tb00498.x Mohieldin, M., Iqbal, Z., Rostom, A., & Fu, X. (2011). The role of Islamic finance in enhancing financial inclusion in Organization of Islamic Cooperation (OIC) countries. World Bank Group: Policy Research Working Paper. doi:10.1596/1813-9450-5920 Neaime, S. & Gaysset. (2018). Financial inclusion and stability in MENA: Evidence from poverty and inequality. Finance Research Letters, 24,230-237. doi:10.1016/j.frl.2017.09.007 Nkwede, F. (2015). Financial inclusion and economic growth in Africa: Insight from Nigeria. European Journal of Business and Management, 7(35), 71-80. Omar, M. A., & Inaba, K. (2020). Does financial inclusion reduce poverty and income inequality in developing countries? A panel data analysis. Journal of economic structures, 9(1), 1-25. doi:10.1186/s40008-020-00214-4 Park, C. Y., & Mercado Jr, R. (2018). Financial inclusion, poverty, and income inequality. The Singapore Economic Review, 63(01), 185-206. doi:10.1142/S0217590818410059 Patrick, H. T. (1966). Financial development and economic growth in underdeveloped countries. Economic development and Cultural change, 14(2), 174-189. Polloni-Silva, E., da Costa, N., Moralles, H. F., & Sacomano Neto, M. (2021). Does financial inclusion diminish poverty and inequality? A panel data analysis for Latin American countries. Social Indicators Research, 158(3), 889-925. Puspitasari, S., Mahri, A. J. W., & Utami, S. A. (2020). Indeks inklusi keuangan syariah di Indonesia tahun 2015-2018. Amwaluna: Jurnal Ekonomi dan Keuangan Syariah, 4(1), 15-31. doi:10.29313/amwaluna.v4i1.5094 Riswanto, A., Tanjung, H., & Devi, A. (2021). Dampak inklusi keuangan dan bank syariah terhadap kesehatan dan pendidikan nasional. El-Mal: Jurnal Kajian Ekonomi & Bisnis Islam, 2(2), 1-26. doi:10.47467/elmal.v2i2.518 Rostow, W. W. (1959). The stages of economic growth. The Economic History Review, 12(1), 1-16. doi:10.2307/2591077 Robinson, J. (1952). The generalization of the general theory. In The Rate of Interest and Other Essays. London: MacMillan. Romer, P. M. (1990). Endogenous technological change. Journal of Political Economy, 98(5):71−102. Romer, P. M. (1986). Increasing returns and long-run growth. Journal of Political, 94(5):1002−1037. Sanjaya, I. M., & Nursechafia, N. (2016). Financial inclusion and inclusive growth: A cross-province analysis in Indonesia. BMEB: Buletin of Monetary Economics and Banking, 18(3), 281-306. doi:10.21098/bemp.v18i3.551 Sarma, M. (2012). Index of financial inclusion–a measure of financial sector inclusiveness. Centre for International Trade and Development, School of International Studies Working Paper Javaharlal Nehru University. Delhi, India. Sarma, M., & Pais, J. (2011). Financial inclusion and development. Journal of International Development, 23(5), 613-628. doi:10.1002/jid.1698 Schumpeter, J. (1911). The theory of economic development: An inquiry into profits, capital, credit, interest and the business cycle. Cambridge: Harvard University Press. Sethi, D., & Acharya, D. (2018). Financial inclusion and economic growth linkage: Some cross country evidence. Journal of Financial Economic Policy, 10(3), 369-385. doi:10.1108/JFEP-11-2016-0073 Simatupang, M., Sinaga, B. M., Hartoyo, S. & Haryanto (2020). Impact of financial inclusion, government expenditures in education and health sectors on human development in Indonesia. Journal of Economic Development, Environment and People, 9(2), 5-17. doi:10.26458/jedep.v9i2.643 Singh, K., & Kondan, A. S. (2011). Financial inclusion, development and its determinants: An empirical evidence of indian states. The Asian Economic Review: Journal of the Indian Institute of Economics, 53(1), 115-134. Siswa, I., & Agustin, G. (2020). Analisis pengaruh inklusi keuangan terhadap indeks pembangunan manusia di Indonesia tahun 2015. Jurnal Ilmiah Ekonomi dan Bisnis, 17(2), 121-130. doi:10.31849/jieb.v17i2.4091 Umar, A. I. (2017). Index of syariah financial inclusion in Indonesia. BMEB: Buletin of Monetary Economics and Banking, 20(1), 99-126. doi:10.21098/bemp.v20i1.726
36
Sousa, W. S. C. de, D. M. A. Melo, J. E. C. da Silva, R. S. Nasar, M. C. Nasar, and J. A. Varela. "Photoluminescence in ZrO2 doped with Y and La." Cerâmica 53, no. 325 (March 2007): 99–103. http://dx.doi.org/10.1590/s0366-69132007000100015.
Анотація:
This study aims to describe the synthesis and optical characterization of a nanometric zirconium oxide solid solution containing yttrium and lanthanum. Zirconium citrate, yttrium nitrate and lanthanum nitrate were mixed in the ratios: 94 mol% of ZrO2 - 6 mol% of Y2O3 and 92 mol% of ZrO2 - 6 mol % of Y2O3 - 2 mol % of La2O3. FTIR analysis shows organic material in decomposition and thermal analysis shows the transformation from the tetragonal to the monoclinic phase of zirconia, the loss of water molecule and zirconium dehydroxylation. The X-ray diffraction analysis shows a homogeneous phase formation of ZrO2-Y2O3-La2O3 demonstrating that lanthanum addition does not cause phase formation, promoting a solid solution based on zirconia with cubic structure. The photoluminescence spectra show absorption bands at 562 nm and 572 nm (350 °C) and specific absorption bands at 543 nm, 561 nm, 614 nm and 641 nm (900 °C). The photoluminescence effect at low temperature is caused by defects such as (Y Zr,Y O)', (2Y Zr,V O)'' and V O. Emissions at 614 nm and 641 nm are caused by O-2p -> Zr-4d transition. An emission at 543 nm can be attributed to LaO8 centers with O-2p -> La-5d transition.
37
Dominic, Olufunmilola L., Abdullahi, M. Muhammad, and Iliasu Y. Seidina. "Awareness of the benefits of ginger use among students of Nigeria army school of education, Sobi-Ilorin, Kwara State." Ghana Journal of Health, Physical Education, Recreation, Sports and Dance (GJOHPERSD) 8 (June 1, 2015): 81–96. http://dx.doi.org/10.47963/gjohpersd.v8i.559.
Анотація:
The objective of this study was to determine the level of awareness, knowledge of benefits and use of ginger among the students of the Nigerian Army School of Education (NASE), Sobi-Ilorin Kwara State. The descriptive survey design was used to elucidate the awareness, knowledge of benefits and practice of ginger use. The population was all 350 students of NASE, Ilorin. They were purposively selected, from which 337 validly participated. The instrument for data collection was a validated researcher structured questionnaire. Test retest reliability was conducted and PPMC coefficient (r = 0.72) was obtained. Frequency and percentage were used for demographic data while t-test was used for testing the hypotheses at 0.05 alpha level. The result revealed that NASE, Ilorin students were highly aware of ginger, 312 (92.6%). There was significant difference between soldiers and officers in; awareness n = 337, t (335) = 4.94, p = 0.001, 2 = .007; health benefits n = 337, t (335) = 2.92, p = 0.004, 2 = .002 and performance purposes n = 337, t (335) = 2.48, p = 0.001, 2 = .002. It was concluded that majority of NASE students are aware of ginger, which they mainly consumed as drinks. Further study is necessary to ascertain the size of benefits and the best way ginger use would enhance the health and job performance of military personnel..
38
Dunshea, F. R., D. K. Kerton, P. D. Cranwell, R. G. Campbell, B. P. Mullan, R. H. King, and J. R. Pluske. "Interactions between weaning age, weaning weight, sex, and enzyme supplementation on growth performance of pigs." Australian Journal of Agricultural Research 53, no. 8 (2002): 939. http://dx.doi.org/10.1071/ar01197.
Анотація:
Digestive capacity of early-weaned pigs may be insufficient to fully digest many ingredients currently used in weaner diets. The aim of this experiment was to determine whether an exogenous enzyme preparation with broad carbohydrase activity could benefit pigs that developmentally might be immature at weaning, especially with regard to gastrointestinal development. Eighty Large White × Landrace pigs were used in a 2 × 2 × 2 × 2 factorial experiment with the factors being: weaning age (14 or 24 days), weaning weight (heavy or light), sex (boar or gilt), and dietary Biofeed Plus CT (0 or 500 μg/g) which contained fungal xylanases, pentosanases and β-glucanases. Pigs were housed individually and given a wheat-based (550 g/kg) diet containing 15.0 MJ DE and 15.9 g lysine/kg on an ad libitum basis for 21 days. The diet also contained 50 g/kg of soybean meal and 50 g/kg of lupin (Lupinus�angustifolius) kernels. The liveweights of heavy (H) pigs weaned at 24 or 14 days and light pigs (L) weaned at 24 or 14 days were 7.9 and 5.3 and 5.2 and 3.9 kg, respectively. Pigs weaned at 14 days grew slower (157 v. 345 g/day) than those weaned at 24 days, although there was a suggestion of an interaction between age and weight at weaning (P = 0.081). Thus, H and L pigs weaned at 14 days grew at 148 and 166 g/day, whereas H and L pigs weaned at 24 days grew at 374 and 315 g/day, respectively. Although there was no main effect of enzymes on daily gain (248 v. 254 g/day, P = 0.80), feed intake (278 v. 284 g/day, P = 0.79), or feed conversion ratio (1.19 v. 1.25, P�=�0.35), there were interactions with weaning age on daily gain (P = 0.050) and feed intake (P = 0.060). Pigs weaned at 14 days grew slower (176 v. 138 g/day) and ate less (206 v. 174 g/day), whereas pigs weaned at 24 days grew faster (321 v. 369 g/day) and ate more (351 v. 394 g/day), when supplemented with enzymes. During the third week after weaning there were interactions between dietary enzymes and sex (P = 0.060) and dietary enzymes and age (P = 0.023) on daily gain. Thus, pigs weaned at 24 days and supplemented with Biofeed Plus CT grew more quickly during the third week (559 v. 460 g/day), whereas the converse was true for pigs weaned at 14 days (286 v. 334 g/day). Also, enzyme-supplemented boars grew better over this period (457 v. 371 g/day), whereas the converse was true for gilts (388 v. 423 g/day). In conclusion, these data clearly indicate that the greatest determinant of post-weaning performance under the present conditions was the age of the pigs at weaning. Dietary enzyme supplementation appeared most efficacious in boars weaned at an older age, although benefits did not become apparent until 2 weeks after weaning.
39
Zhang, Li, Zheng G. Zhang, Michael Chopp, Peter J. Elliott, and Julian Adams. "Effects of PS-519 combined with thrombolytic therapy in embolic stroke in rat." Stroke 32, suppl_1 (January 2001): 351. http://dx.doi.org/10.1161/str.32.suppl_1.351-a.
Анотація:
P67 We evaluated the effect of a proteasome inhibitor (PS-519) which blocks the activation of NF-kB, alone or combination with thrombolysis, on ischemic cell damage after embolic stroke in rat. Male Wistar rats (n=44) were subjected to embolic middle cerebral artery (MCA) occlusion. Animals were randomly assigned into seven groups: PS-519 treatment groups (n=6 each group) were infused intravenously with PS-519(1.0 mg/kg) at 2 h, 4 h, or 6 h after MCA occlusion, respectively. Combination treatment groups (n=6 each group) PS-519(1.0 mg/kg) followed by rtPA (10 mg/kg) were administered at 2 h, 4 h, or 6 h after MCA occlusion. A control group (n=8) was administered saline at 2 h after MCA occlusion. Rats were sacrificed 7 days after MCA occlusion, infarct volume and gross hemorrhage were measured. In PS-519 treatment groups: infarct volume was significantly (p<0.05) reduced by PS-519 treatment at 2 (19”3.5%) and 4 h (22“3.1%) after MCA occlusion when compared with the control group (34”3.5%). However, no significant reduction of lesion volume was found in the 6 hour treated group (34“2.5%). In the combination treatment groups: infarction volume was significantly (p<0.05) reduced in all three groups compared with control: 2 h (18”4.3%), 4 h (21“3.6%), 6 h (21”4.4%). None of treated rats and 25% of control rats had intracerebral gross hemorrhage. Significant reductions (p<0.05) in neurological deficit and body weight loss were found in all treated groups except the group that treated with PS-519 alone at 6 h. Our results demonstrate that administration of PS-519 alone, or combination with rtPA significantly reduces ischemic cell damage. Moreover, combination treatment with PS-519 and rtPA expands the therapeutic window to at least 6 h after embolic stroke. This suggests that combination therapy might lead to improved neurological outcome beyond that which would occur with neuroprotective treatment or thrombolytics alone.
40
Bataleva, Yuliya V., Aleksei N. Kruk, Ivan D. Novoselov, Olga V. Furman, and Yuri N. Palyanov. "Decarbonation Reactions Involving Ankerite and Dolomite under upper Mantle P,T-Parameters: Experimental Modeling." Minerals 10, no. 8 (August 13, 2020): 715. http://dx.doi.org/10.3390/min10080715.
Анотація:
An experimental study aimed at the modeling of dolomite- and ankerite-involving decarbonation reactions, resulting in the CO2 fluid release and crystallization of Ca, Mg, Fe garnets, was carried out at a wide range of pressures and temperatures of the upper mantle. Experiments were performed using a multi-anvil high-pressure apparatus of a “split-sphere” type, in CaMg(CO3)2-Al2O3-SiO2 and Ca(Mg,Fe)(CO3)2-Al2O3-SiO2 systems (pressures of 3.0, 6.3 and 7.5 GPa, temperature range of 950–1550 °C, hematite buffered high-pressure cell). It was experimentally shown that decarbonation in the dolomite-bearing system occurred at 1100 ± 20 °C (3.0 GPa), 1320 ± 20 °C (6.3 GPa), and 1450 ± 20 °C (7.5 GPa). As demonstrated by mass spectrometry, the fluid composition was pure CO2. Composition of synthesized garnet was Prp83Grs17, with main Raman spectroscopic modes at 368–369, 559–562, and 912–920 cm−1. Decarbonation reactions in the ankerite-bearing system were realized at 1000 ± 20 °C (3.0 GPa), 1250 ± 20 °C (6.3 GPa), and 1400 ± 20 °C (7.5 GPa). As a result, the garnet of Grs25Alm40Prp35 composition with main Raman peaks at 349–350, 552, and 906–907 cm−1 was crystallized. It has been experimentally shown that, in the Earth’s mantle, dolomite and ankerite enter decarbonation reactions to form Ca, Mg, Fe garnet + CO2 assemblage at temperatures ~175–500 °C lower than CaCO3 does at constant pressures.
41
Reddy, Manasa. "Linking D-Dimer and haematological parameters among Indian COVID 19 patients." Bioinformation 19, no. 12 (December 31, 2023): 1179–83. http://dx.doi.org/10.6026/973206300191179.
Анотація:
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak continues to place a significant strain on healthcare systems, economies, and patient management. Therefore, it is of interest to evaluate the role of D-Dimer and haematological parameters to identify severity and outcome of COVID 19 patients. Total 100 cases diagnosed with COVID 19 were recruited in the study and followed up for 6 months. The subjects were grouped into 2, Group 1: Newly Diagnosed COVID 19 Patients and Group 2: After 6 months of follow up COVID 19 Patients. We analyzed Hb, RBCs, WBCs, PT, APTT and D-Dimer and also, we taken CT values of the study subjects. A statistical analysis was done by using SPSS version 20.0. The WBCs and haemoglobin mean values are shown significant values between the study subjects, respectively with p-values < 0.001**. The PT and APTT significantly increased in newly diagnosed COVID 19 patients when compared to after 6 months of follow up at p–value < 0.001**. There was a positive correlation of WBCs, PT, APTT (r= 0.458, 526, 509) with D-Dimer and negatively correlated RBCS, Hb, CT (-0.056, 321, 526, 353), respectively at p < 0.001**. Thus, low platelet, high d-dimer, and fibrinogen may serve as risk markers for the progression of COVID-19 severity. Hence, COVID-19 patients may experience anaemia-related consequences as hypoxia, coronary and pulmonary failure due to low Hb concentration. Further, patients with COVID-19 also experience bleeding issues due to thrombocytopenia.
42
Jain, Amit, Hamid Hassanzadeh, Varun Puvanesarajah, Eric O. Klineberg, Daniel M. Sciubba, Michael P. Kelly, D. Kojo Hamilton, et al. "Incidence of perioperative medical complications and mortality among elderly patients undergoing surgery for spinal deformity: analysis of 3519 patients." Journal of Neurosurgery: Spine 27, no. 5 (November 2017): 534–39. http://dx.doi.org/10.3171/2017.3.spine161011.
Анотація:
OBJECTIVEUsing 2 complication-reporting methods, the authors investigated the incidence of major medical complications and mortality in elderly patients after surgery for adult spinal deformity (ASD) during a 2-year follow-up period.METHODSThe authors queried a multicenter, prospective, surgeon-maintained database (SMD) to identify patients 65 years or older who underwent surgical correction of ASD from 2008 through 2014 and had a minimum 2 years of follow-up (n = 153). They also queried a Centers for Medicare & Medicaid Services claims database (MCD) for patients 65 years or older who underwent fusion of 8 or more vertebral levels from 2005 through 2012 (n = 3366). They calculated cumulative rates of the following complications during the first 6 weeks after surgery: cerebrovascular accident, congestive heart failure, deep venous thrombosis, myocardial infarction, pneumonia, and pulmonary embolism. Significance was set at p < 0.05.RESULTSDuring the perioperative period, rates of major medical complications were 5.9% for pneumonia, 4.1% for deep venous thrombosis, 3.2% for pulmonary embolism, 2.1% for cerebrovascular accident, 1.8% for myocardial infarction, and 1.0% for congestive heart failure. Mortality rates were 0.9% at 6 weeks and 1.8% at 2 years. When comparing the SMD with the MCD, there were no significant differences in the perioperative rates of major medical complications except pneumonia. Furthermore, there were no significant intergroup differences in the mortality rates at 6 weeks or 2 years. The SMD provided greater detail with respect to deformity characteristics and surgical variables than the MCD.CONCLUSIONSThe incidence of most major medical complications in the elderly after surgery for ASD was similar between the SMD and the MCD and ranged from 1% for congestive heart failure to 5.9% for pneumonia. These complications data can be valuable for preoperative patient counseling and informed consent.
43
Zhang, Rui-Juan, Dan Zhao, Qiu Zhong, Ya-Li Xue, and Guang-Xu Huang. "Na3Sm(PO4)2: (3+1)-dimensional commensurately modulated structure model and photoluminescence properties." Zeitschrift für Kristallographie - Crystalline Materials 234, no. 5 (May 27, 2019): 281–89. http://dx.doi.org/10.1515/zkri-2018-2095.
Анотація:
Abstract For the first time, we determined the detailed crystal structure of Na3Sm(PO4)2 using single crystal X-ray diffraction and established the commensurately modulated structure model using the superspace formalism. The structure adopts a (3+1)-dimensional superspace group Pca21(0β0)000 with the modulation vector q=1/3b*. At the same time, the photoluminescent properties of Na3Sm(PO4)2 sintered at different temperatures between 800 and 1200°C were studied. Under near-UV excitation (402 nm), Na3Sm(PO4)2 shows intense characteristic emission bands of Sm3+ (561, 596, 642 nm) with the CIE coordinate of (0.5709, 0.4282), corresponding to orange color. The excitation spectrum covers a wide range from 350 nm to 470 nm, which indicates that Na3Sm(PO4)2 can be efficiently activated by near-UV or visuable LED ship.
44
Musset, Alain. "« L'eau dans la société médiévale : fonction, enjeux, images », Mélanges de l'École française de Rome, t. 104-2, Moyen Age, 1992, pp. 341-565." Annales. Histoire, Sciences Sociales 50, no. 3 (June 1995): 690–93. http://dx.doi.org/10.1017/s0395264900057802.
45
Klein, Pamela, Peter Ordentlich, William McCulloch, Scott Cruickshank, Miranda Rees, and Denise Aysel Yardley. "Characterization of the overall survival benefit in ENCORE 301, a randomized placebo-controlled phase II study of exemestane with and without entinostat in ER+ postmenopausal women with metastatic breast cancer." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 567. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.567.
Анотація:
567 Background: Histone deacetylase inhibitors (HDACi) prevent the emergence of drug tolerant clones and sensitize cells to a variety of anti-cancer therapies. We previously reported ENCORE 301, a randomized placebo controlled phase 2 study comparing exemestane with (EE) and without (EP) the HDACi entinostat met its primary endpoint of prolonging progression free survival (PFS) (4.3 months vs 2.3 months) and extending overall survival (OS) benefit (26.9 vs 19.8 months). In order to characterize and better understand the OS benefit, exploratory analyses were conducted. Methods: Hazard ratios (HR) for treatment were estimated from the Cox proportional hazards model, with EP serving as the reference treatment in the calculations. Inferential comparisons between treatment groups were made using the log-rank test. Results: Analysis of OS across multiple subsets of interest demonstrated a consistent benefit in EE group versus EP. Sensitivity analysis of baseline characteristics potentially impacting OS did not identify any factors that influenced the effect of EE on OS. Examination of treatments received during follow-up after discontinuation of EE and EP demonstrated balance between treatment group for patients receiving chemotherapy (48% EE: 44% EP), hormone therapy (37% EE: 35% EP), bisphosphonates (2% EE; 0% EP), radiation (6% EE; 5%EP), and surgery (0% EE: 2% EP). Compared to EP, OS was longer in EE group for patients whose first subsequent treatment was a hormone therapy (EE median not reached vs EP median 20.5 months; HR 0.65 [95% CI 0.26, 1.58]) or chemotherapy (EE median 26.9 months vs EP median 17.6 months; HR 0.51 [95% CI 0.25, 1.04]). Updated PFS and OS data will also be presented along with correlation analysis of PFS and OS. Conclusions: Analyses of baseline characteristics, subsequent treatment and subsets of prognostic factors in ENCORE 301 did not identify any contributing factors that account for the extended OS benefit in the EE treatment group. Long lasting effects of entinostat on progenitor cells, emergence of drug tolerant cells and or priming to subsequent therapies cannot be ruled out.
46
E. Zelal DÜZGÜN and Necat TOĞAY. "The Effects of Different Planting Densities on Lentil (Lens culinaris Medic.) Yield and Yield Components in Mardin Conditions." ISPEC Journal of Agricultural Sciences 5, no. 3 (September 4, 2021): 560–67. http://dx.doi.org/10.46291/ispecjasvol5iss3pp560-567.
Анотація:
In this study, the effects of four different sowing densities (200, 250, 300 and 350 seed m-2) on the yield and yield components for two winter lentil cultivars (Şakar and Fırat-87) in Mardin conditions. The study was laid out in a factorial randomised block design with three replicates at the fields of Mardin Artuklu University, Kızıltepe Vocational High School in 2012-2013 growing season. In the study were investigated the effect of planting densities on the plant height, first pod height, numbers of branche, numbers of pod per plant and numbers of seed per plant, numbers of seed per pod, seed yield per unit area, harvest index, biological yield and 1000 seed weight. While the highest seed yield per area was obtained from second plant density and Şakar variety with 275.23 kg da-1, the lowest seed yield per area was obtained from first plant density and Fırat-87 variety with 208.83 kg da-1.
47
Racu, Andrei, Marius Stef, Gabriel Buse, Irina Nicoara, and Daniel Vizman. "Luminescence Properties and Judd–Ofelt Analysis of Various ErF3 Concentration-Doped BaF2 Crystals." Materials 14, no. 15 (July 28, 2021): 4221. http://dx.doi.org/10.3390/ma14154221.
Анотація:
The influence of erbium ion concentration on the optical properties of BaF2:ErF3 crystals was investigated. Four ErF3 concentration (0.05, 0.08, 0.15 and 0.5 mol% ErF3)-doped BaF2 crystals were obtained using the Bridgman technique. Room temperature optical absorption in the 250–850 nm spectral range was measured, and the photoluminescence (PL) and decay times were also investigated. The Judd–Ofelt (JO) approximation was used, taking into account four absorption peaks (at 377, 519, 653 and 802 nm). The JO intensity parameters, Ωt (t = 2, 4, 6), were calculated. The influence of the ErF3 concentration on the JO parameters, branching ratio, radiative transition probability and radiative lifetime were studied. The obtained results were compared with measured values and with those reported in the literature. Under excitation at 380 nm, the well-known green (539 nm) and red (668 nm) emissions were obtained. The calculated and experimental radiative lifetimes were in millisecond range for green and red emissions. The intensity of the PL spectra varied with the Er3+ ion concentration. The emission intensity increased linearly or exponentially, depending on the ErF3 concentration. Under excitation at 290 nm, separate to the green and red emissions, a new UV emission band (at 321 nm) was obtained. Other research has not reported the UV emission or the influence of ErF3 concentration on emission behavior.
48
Weisel, Katja C., Jesus San Miguel, Gordon Cook, Merav Leiba, Kenshi Suzuki, Shaji Kumar, Michele Cavo, et al. "Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 8006. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.8006.
Анотація:
8006 Background: In 2 randomized phase 3 trials of RRMM patients (pts), DRd (POLLUX) or DVd (CASTOR) significantly improved PFS and deepened responses compared with Rd or Vd alone, respectively. The novel mechanism of action of daratumumab (D) may improve the poor prognosis associated with high-risk cytogenetic abnormalities in RRMM. Therefore, we examined the efficacy of DRd and DVd among RRMM pts with standard (std) or high cytogenetic risk status. Methods: Bone marrow aspirates were collected at screening and assessed centrally via next generation sequencing (NGS). Pts with high-risk cytogenetics included those who had ≥1 of the following abnormalities: t(4;14), t(14;16), or del17p; std-risk pts were defined as those confirmed negative for these abnormalities. Efficacy analyses included PFS and ORR. Results: Samples from 311/569 pts in POLLUX and 353/498 pts in CASTOR were assessed via NGS. In POLLUX, the median duration of follow-up was 17.3 months. Significantly longer median PFS and numerically higher ORR were observed with DRd vs Rd among high-risk patients, and significant improvements in these outcomes were observed in std-risk patients (Table). In CASTOR, the median duration of follow-up was 13.0 months. Significantly longer median PFS and higher ORR were observed with DVd vs Vd among both high- and std-risk pts (Table). Concordance rates for t(4;14), t(14;16), and del17p were high (88%-98%) between NGS and FISH. Updated data, including subgroup analyses, will be presented. Conclusions: In RRMM pts, the addition of D to standard-of-care regimens improved outcomes regardless of cytogenetic risk status. Targeting CD38 by combining D with Rd or Vd appears to improve the poor outcomes associated with high-risk cytogenetic status. See table. Clinical trial information: NCT02136134 and NCT02076009. [Table: see text]
49
Pelizzo, Maria Rosa, Paolo Bernante, Antonio Toniato, and Ambrogio Fassina. "Frequency of Thyroid Carcinoma in a Recent Series of 539 Consecutive Thyroidectomies for Multinodular Goiter." Tumori Journal 83, no. 3 (May 1997): 653–55. http://dx.doi.org/10.1177/030089169708300305.
Анотація:
Aims and background The aim of the study was to analyze the frequency of thyroid carcinoma in a consecutive series of 539 thyroidectomies for multinodular goiter (MNG) and to assess the influence of sex and age as cancer risk factors. Methods In a 2-year period, 539 patients underwent subtotal or total thyroidectomy for MNG at the Institute of General Surgery, University of Padova, Padova, Italy: 455 were females and 84 males (F/M = 5.5/1); mean age was 46 years (min. 17, max 78). Only 17 patients (3.1%) (16 females and 1 male) were aged 21 years or less. Results A malignancy was found in 41 patients: 38 females and 3 males; 39 older and 2 younger than 21 years. The frequency of cancer in MNG was 7.6%: 8.3% in females and 3.6% in males; 7.5% in patients older than 21 and 11.7% under 21 years. Conclusions The combination of MNG and carcinoma should always be carefully considered but not overemphasized, and the policy of surgically treating all patients with MNG is not justified. Sex and age cannot be considered as factors of a higher risk of cancer.
50
MacInnis, Martin J., Christine E. Dziedzic, Emily Wood, Sara Y. Oikawa та Stuart M. Phillips. "Presleep α-Lactalbumin Consumption Does Not Improve Sleep Quality or Time-Trial Performance in Cyclists". International Journal of Sport Nutrition and Exercise Metabolism 30, № 3 (1 травня 2020): 197–202. http://dx.doi.org/10.1123/ijsnem.2020-0009.
Анотація:
We tested the hypothesis that presleep consumption of α-lactalbumin (LA), a fraction of whey with a high abundance of tryptophan, would improve indices of sleep quality and time-trial (TT) performance in cyclists relative to an isonitrogenous collagen peptide (CP) supplement lacking tryptophan. Using randomized, double-blind, crossover designs, cyclists consumed either 40 g of LA or CP 2 hr prior to sleep. In Study 1, six elite male endurance track cyclists (age 23 ± 6 years, 70.2 ± 4.4 ml·kg−1·min−1) consumed a supplement for three consecutive evenings before each 4-km TT on a velodrome track, whereas in Study 2, six well-trained cyclists (one female; age 24 ± 5 years, 66.9 ± 8.3 ml·kg−1·min−1) consumed a supplement the evening before each 4-km TT on a stationary cycle ergometer. Indices of sleep quality were assessed with wrist-based actigraphy. There were no differences between the CP and LA supplements in terms of total time in bed, total sleep time, or sleep efficiency in Study 1 (LA: 568 ± 71 min, 503 ± 67 min, 88.3% ± 3.4%; CP: 546 ± 30 min, 479 ± 35 min, 87.8% ± 3.1%; p = .41, p = .32, p = .74, respectively) or Study 2 (LA: 519 ± 90 min, 450 ± 78 min, 87.2% ± 7.6%; CP: 536 ± 62 min, 467 ± 57 min, 87.3% ± 6.4%; p = .43, p = .44, p = .97, respectively). Similarly, time to complete the 4-km TT was unaffected by supplementation in Study 1 (LA: 274.9 ± 7.6 s; CP: 275.5 ± 7.2 s; p = .62) and Study 2 (LA: 344.3 ± 22.3 s; CP: 343.3 ± 23.0 s; p = .50). Thus, relative to CP, consuming LA 2 hr prior to sleep over 1–3 days did not improve actigraphy-based indices of sleep quality or 4-km TT performance in cyclists.